<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">2895614</article-id><article-id pub-id-type="publisher-id">1471-2407-10-283</article-id><article-id pub-id-type="pmid">20540789</article-id><article-id pub-id-type="doi">10.1186/1471-2407-10-283</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Snoussi</surname><given-names>Kaouther</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>naftikaouther@yahoo.fr</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Mahfoudh</surname><given-names>Wijden</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>wijdene_mahfoudh@yahoo.fr</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Bouaouina</surname><given-names>Noureddine</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>noureddine.bouaouina@rns.tn</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Fekih</surname><given-names>Meriem</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>fekihm2002@yahoo.fr</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Khairi</surname><given-names>Hedi</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>hedi.khairi@rns.tn</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Helal</surname><given-names>Ahmed N</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>Ahmed.Helal@fphm.rnu.tn</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Chouchane</surname><given-names>Lotfi</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I5">5</xref><email>loc2008@qatar-med.cornell.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>Laboratoire d'Immuno-Oncologie Moléculaire, Faculté de Médecine de Monastir, Université de Monastir, Monastir, 5019, Tunisia</aff><aff id="I2"><label>2</label>Départment de Cancérologie Radiothérapie, CHU Farhat Hached, Sousse, 4000, Tunisia</aff><aff id="I3"><label>3</label>Service d'Obstétrique et des maladies féminines, Centre Hospitalo-Universitaire-Farhat-Hached de Sousse, Sousse, 4000, Tunisia</aff><aff id="I4"><label>4</label>Unité Génome, Diagnostic Immunitaire et Valorisation, Institut Supérieur de Biotechnologie de Monastir, Université de Monastir, Monastir, 5000, Tunisia</aff><aff id="I5"><label>5</label>Department of Genetic Medicine, Weill Cornell Medical College in Qatar, P.O.Box 24144, Doha, Qatar</aff><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>12</day><month>6</month><year>2010</year></pub-date><volume>10</volume><fpage>283</fpage><lpage>283</lpage><history><date date-type="received"><day>14</day><month>10</month><year>2009</year></date><date date-type="accepted"><day>12</day><month>6</month><year>2010</year></date></history><permissions><copyright-statement>Copyright ©2010 Snoussi et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2010</copyright-year><copyright-holder>Snoussi et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2407/10/283"/><abstract><sec><title><text><SENT sid="1" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Interleukin-8 (IL-8/CXCL-8) is a prototype of the ELR+CXC chemokines that play an important role in the promotion and progression of many human cancers including breast cancer. </plain></SENT>
<SENT sid="3" pm="."><plain>We have recently showed the implication of polymorphism (-251) T/A of IL-8 gene in the susceptibility and prognosis of breast carcinoma. </plain></SENT>
<SENT sid="4" pm="."><plain>IL-8 acts through its CXCR1 and CXCR2 receptors. </plain></SENT>
<SENT sid="5" pm="."><plain>CXCR2, expressed on the endothelial cells, is the receptor involved in mediating the angiogenic effects of ELR+CXC chemokines and in particular IL-8. </plain></SENT>
</text></SecTag></p><p><SecTag type="ABS"><text><SENT sid="6" pm="."><plain>In the current study, we investigated the susceptibility and prognostic implications of the genetic variation in CXCR2 in breast carcinoma. </plain></SENT>
<SENT sid="7" pm="."><plain>We also confirmed the implication of IL-8 (-251) T/A polymorphism in a larger cohort. </plain></SENT>
<SENT sid="8" pm="."><plain>Finally, we combined the IL-8 and CXCR2 variant alleles and analyzed their effects in breast cancer risk and prognosis. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="9" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="10" pm="."><plain>We used the allele-specific polymerase chain reaction to characterize the variation of IL-8 and CXCR2 for 409 unrelated Tunisian patients with breast carcinoma and 301 healthy control subjects. </plain></SENT>
<SENT sid="11" pm="."><plain>To estimate the relative risks, Odds ratios and 95% confidence intervals were calculated using unconditional logistic regression after adjusting for the known risk factors for breast cancer. </plain></SENT>
<SENT sid="12" pm="."><plain>Associations of the genetic marker with the rates of breast carcinoma-specific overall survival and disease-free survival were assessed using univariate and multivariate analyses. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="13" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="14" pm="."><plain>A highly significant association was found between the homozygous CXCR2 (+ 1208) TT genotype (adjusted OR = 2.89; P = 0.008) and breast carcinoma. </plain></SENT>
<SENT sid="15" pm="."><plain>A significantly increased risk of breast carcinoma was associated with IL-8 (-251) A allele (adjusted OR = 1.86; P = 0.001). </plain></SENT>
<SENT sid="16" pm="."><plain>The presence of two higher risk genotypes (the TA and TT in IL-8, and the TT in CXCR2) significantly increased the risk of developing breast carcinoma (adjusted OR = 4.15; P = 0.0004). </plain></SENT>
</text></SecTag></p><p><SecTag type="ABS"><text><SENT sid="17" pm="."><plain>The CXCR2 (+ 1208) T allele manifested a significant association with an aggressive phenotype of breast carcinoma as defined by a large tumor size, a high histological grade, and auxiliary's lymph node metastasis. </plain></SENT>
<SENT sid="18" pm="."><plain>A significant association between the IL-8 (-251) A allele and the aggressive form of breast carcinoma was also found. </plain></SENT>
</text></SecTag></p><p><SecTag type="ABS"><text><SENT sid="19" pm="."><plain>Moreover, the presence of the IL-8 (-251) A and/or the CXCR2 (+ 1208) T allele showed a significant association with a decreased overall survival and disease-free survival in breast carcinoma patients. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="20" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="21" pm="."><plain>Our results indicated that the polymorphisms in IL-8 and CXCR2 genes are associated with increased breast cancer risk, as well as disease progress, supporting our hypothesis for IL-8 and ELR+CXC chemokine receptor (CXCR2) involvement in breast cancer pathogenesis. </plain></SENT>
</text></SecTag></p></sec></abstract></article-meta></front><body><SecTag type="INTRO"><sec><title><text><SENT sid="22" pm="."><plain>Background </plain></SENT>
</text></title><p><text><SENT sid="23" pm="."><plain>Breast cancer is one of the most prevalent cancers in the world. </plain></SENT>
<SENT sid="24" pm="."><plain>Despite progress made in the last 30 years in breast cancer screening and treatment, this disease is still responsible for almost half a million deaths per year worldwide. </plain></SENT>
<SENT sid="25" pm="."><plain>Approximately half of diagnosed patients will eventually develop metastatic disease. </plain></SENT>
<SENT sid="26" pm="."><plain>Treatment for metastatic breast cancer is palliative, and median life expectancy after recurrence is between 24 and 30 months or less [1,2]. </plain></SENT>
</text></p><p><text><SENT sid="27" pm="."><plain>The etiology of breast cancer is extremely complex and, while not yet elucidated, appears to involve numerous genetic, endocrine and external environmental factors. </plain></SENT>
<SENT sid="28" pm="."><plain>The role of genetic factors in epidemiology and pathogenesis of both sporadic and familial breast cancer is now well established. </plain></SENT>
<SENT sid="29" pm="."><plain>Only a small minority (~5%) of patients with breast cancer develop the disease as a result of inheritance of germline mutations in dominant, highly penetrant susceptibility genes such as BRCA1 and BRCA2. </plain></SENT>
<SENT sid="30" pm="."><plain>However, polymorphisms in the genes involved in the complex mechanisms of carcinogenesis may confer low penetrant susceptibility to breast cancer in a significant proportion of the remaining patients [3]. </plain></SENT>
</text></p><p><text><SENT sid="31" pm="."><plain>The neoplastic transformation, growth, survival, invasion, and metastases are dependent on the establishment of a pro-angiogenic environment. </plain></SENT>
<SENT sid="32" pm="."><plain>Local angiogenesis is determined by an imbalance in the over-expression of pro-angiogenic factors, as compared to inhibitors of angiogenesis. </plain></SENT>
<SENT sid="33" pm="."><plain>The CXC chemokine family is the unique group of cytokines known for their ability to behave in a disparate manner in angiogenesis regulation. </plain></SENT>
<SENT sid="34" pm="."><plain>Several members of the CXC chemokine are potent promoters of angiogenesis, whereas others inhibit the angiogenic process. </plain></SENT>
<SENT sid="35" pm="."><plain>The disparity in angiogenic activity among CXC chemokine family members is attributed to three amino acid structural domains at the N terminus, Glu-Leu-Arg (ELR), which is present in angiogenic (i.e., CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8) [4-6], but not angiostatic (i.e., CXCL4, CXCL9, CXCL10, and CXCL11) CXC chemokines [7]. </plain></SENT>
</text></p><p><text><SENT sid="36" pm="."><plain>ELR+ CXC chemokines play an important role in tumor growth and progression in a number of tumor model systems [8]. </plain></SENT>
<SENT sid="37" pm="."><plain>In particular, interleukin-8 (IL-8/CXCL8), which was originally described as a leukocyte chemoattractant [9], was subsequently found to possess mitogenic and angiogenic properties [10,11]. </plain></SENT>
<SENT sid="38" pm="."><plain>Several studies suggested a tendency toward the involvement of IL-8 in cancer development [12]. </plain></SENT>
<SENT sid="39" pm="."><plain>Elevated IL-8 levels were associated with disease progression and recurrence in human prostate, lung, gastric, and breast cancers [13-16]. </plain></SENT>
</text></p><p><text><SENT sid="40" pm="."><plain>All angiogenic ELR+ CXC chemokines mediate their angiogenic activity through CXCR2 [17]. </plain></SENT>
<SENT sid="41" pm="."><plain>Subsequent studies have confirmed the expression of CXCR2, not CXCR1, to be the primary functional chemokine receptor in mediating endothelial cell chemotaxis [18,19]. </plain></SENT>
<SENT sid="42" pm="."><plain>By considering the expression of IL-8 by breast cancer cells and CXCR2 by large vessel and microvascular endothelial cells [19,20], an autocrine effect for IL-8 and the chemokine receptor CXCR2 has been suggested. </plain></SENT>
</text></p><p><text><SENT sid="43" pm="."><plain>Promoter regions of a number of cytokine genes contain polymorphisms that directly influence cytokine production [21]. </plain></SENT>
<SENT sid="44" pm="."><plain>The IL-8 gene is located on chromosome 4q13-21 and consists of four exons, three introns, and a proximal promoter region [22]. </plain></SENT>
<SENT sid="45" pm="."><plain>Several polymorphisms have been reported in the IL-8 gene. </plain></SENT>
<SENT sid="46" pm="."><plain>Interestingly, IL-8 production can be controlled by the -251 A/T in the promoter region of this chemokine [23]. </plain></SENT>
<SENT sid="47" pm="."><plain>Recent data revealed that the IL-8 (-251) A allele is associated with a high expression level of IL-8 protein and a severe neutrophil infiltration [23].Other studies also reported that the IL-8 (-251) T/A polymorphism is associated with a higher risk of developing malignant diseases [24-27]. </plain></SENT>
</text></p><p><text><SENT sid="48" pm="."><plain>Three single polymorphisms at positions +785 C/T, +1208 T/C and +1440 G/A were reported in the CXCR2 gene [28]. </plain></SENT>
<SENT sid="49" pm="."><plain>Several reports indicated that the polymorphism +1208 C/T which is located in the non-coding region of CXCR2 gene might provide valuable information for the pathogenesis and the susceptibility to chronic inflammatory disease [28,29]. </plain></SENT>
</text></p><p><text><SENT sid="50" pm="."><plain>Previously we have reported an elevated risk for breast cancer among the Tunisian population (n = 308 cases and n = 236 healthy controls) associated with the IL-8 (-251) T/A polymorphism. </plain></SENT>
<SENT sid="51" pm="."><plain>The implication of this polymorphism in the prognosis of breast carcinoma has also been demonstrated [30]. </plain></SENT>
</text></p><p><text><SENT sid="52" pm="."><plain>Based on the abundant evidence for the role of IL-8 and CXCR2 in carcinogenesis, we evaluated in this study the association of CXCR2 (+ 1208) C/T gene polymorphism and breast cancer susceptibility and prognosis in Tunisia. </plain></SENT>
<SENT sid="53" pm="."><plain>Then we used existing and additional genotype data on 409 breast cancer cases and 301 healthy controls to examine the potential contribution of the combined genotypes of IL-8 and CXCR2 in breast carcinoma occurrence, clinico-pathological characteristics and prognosis. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="methods"><title><text><SENT sid="54" pm="."><plain>Methods </plain></SENT>
</text></title><sec><title><text><SENT sid="55" pm="."><plain>Patients and controls </plain></SENT>
</text></title><p><text><SENT sid="56" pm="."><plain>IL-8 and CXCR2 genotype and allele frequencies were determined in a group of 301 control subjects and 409 patients with breast carcinoma. </plain></SENT>
<SENT sid="57" pm="."><plain>Controls and patients were selected from the same population living in the middle coast of Tunisia and including unrelated subjects. </plain></SENT>
</text></p><p><text><SENT sid="58" pm="."><plain>Data on patient, tumour and treatment characteristics at the study entry for each subject were collected from the department of Radiation Oncology and Medical Oncology of Sousse Hospital (Sousse, Tunisia) between 1996 and 2004. </plain></SENT>
<SENT sid="59" pm="."><plain>They were selected consecutively whenever practically feasible. </plain></SENT>
</text></p><p><text><SENT sid="60" pm="."><plain>All patients included in this study had primary breast carcinoma, with unilateral breast tumours and with no family history for the disease. </plain></SENT>
<SENT sid="61" pm="."><plain>The diagnosis of cancer was confirmed by histopathological analyses. </plain></SENT>
<SENT sid="62" pm="."><plain>The patients (n = 409) had a mean age of 48.0 ± 24.3 (SD) years. </plain></SENT>
<SENT sid="63" pm="."><plain>At time of analysis, 88 patients experienced recurrence (local or distant). </plain></SENT>
<SENT sid="64" pm="."><plain>Among them, 56 died from breast carcinoma (63.64%). </plain></SENT>
<SENT sid="65" pm="."><plain>Table 1 shows the treatment description of all patients. </plain></SENT>
<SENT sid="66" pm="."><plain>A total of 301 healthy women having a mean age of 48.0 ± 14.9 years, were blood donors with no evidence of any personal or family history of cancer (or other serious illness). </plain></SENT>
<SENT sid="67" pm="."><plain>Samples from healthy controls were collected consecutively between 1996 and 2004. </plain></SENT>
<SENT sid="68" pm="."><plain>Control individuals were frequency matched to the expected age distribution of the cases and were from the same geographical area. </plain></SENT>
<SENT sid="69" pm="."><plain>General characteristics of breast cancer patients and healthy controls women are summarized in Table 1. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><text><SENT sid="70" pm="."><plain>The general characteristics of breast cancer patients and healthy controls from Tunisian women blood donors </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><text><SENT sid="71" pm="."><plain>Characteristics, n (%)a </plain></SENT>
</text></th><th align="center"><text><SENT sid="72" pm="."><plain>Cases </plain></SENT>
</text></th><th align="center"><text><SENT sid="73" pm="."><plain>Controls </plain></SENT>
</text></th><th align="center"><text><SENT sid="74" pm="."><plain>P-valueb </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left"><text><SENT sid="75" pm="."><plain>Ageb, yr </plain></SENT>
</text></td><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="76" pm="."><plain>Mean ± SD </plain></SENT>
</text></td><td align="center"><text><SENT sid="77" pm="."><plain>48.0 ± 24. </plain></SENT>
</text></td><td align="center"><text><SENT sid="78" pm="."><plain>48.0 ± 14.9 </plain></SENT>
</text></td><td align="center"><text><SENT sid="79" pm="."><plain>0.97 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="80" pm="."><plain>Body mass index (BMI, kg/m2) </plain></SENT>
</text></td><td align="center"><text><SENT sid="81" pm="."><plain>24.1 ± 5.4 </plain></SENT>
</text></td><td align="center"><text><SENT sid="82" pm="."><plain>20.6 ± 2.5 </plain></SENT>
</text></td><td align="center"><text><SENT sid="83" pm="."><plain>0.0004 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="84" pm="."><plain>History of benign breast disease </plain></SENT>
</text></td><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="85" pm="."><plain>No </plain></SENT>
</text></td><td align="center"><text><SENT sid="86" pm="."><plain>241 (58.92) </plain></SENT>
</text></td><td align="center"><text><SENT sid="87" pm="."><plain>154 (45.18) </plain></SENT>
</text></td><td/></tr><tr><td align="left"><text><SENT sid="88" pm="."><plain>Yes </plain></SENT>
</text></td><td align="center"><text><SENT sid="89" pm="."><plain>168 (41.08) </plain></SENT>
</text></td><td align="center"><text><SENT sid="90" pm="."><plain>147 (54.82) </plain></SENT>
</text></td><td align="center"><text><SENT sid="91" pm="."><plain>0.039 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="92" pm="."><plain>Use of oral contraceptive </plain></SENT>
</text></td><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="93" pm="."><plain>No </plain></SENT>
</text></td><td align="center"><text><SENT sid="94" pm="."><plain>143 (34.96) </plain></SENT>
</text></td><td align="center"><text><SENT sid="95" pm="."><plain>141 (46.84) </plain></SENT>
</text></td><td/></tr><tr><td align="left"><text><SENT sid="96" pm="."><plain>Yes </plain></SENT>
</text></td><td align="center"><text><SENT sid="97" pm="."><plain>266 (65.04) </plain></SENT>
</text></td><td align="center"><text><SENT sid="98" pm="."><plain>160 (53.16) </plain></SENT>
</text></td><td align="center"><text><SENT sid="99" pm="."><plain>0.001 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="100" pm="."><plain>a Cases: n = 409; Controls: n = 301. </plain></SENT>
<SENT sid="101" pm="."><plain>The percentages were shown in the parentheses </plain></SENT>
</text></p><p><text><SENT sid="102" pm="."><plain>b Age and BMI were determined by two-sample t tests; history of benign breast disease and oral contraceptive drugs usage were determined by chi-square tests. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="103" pm="."><plain>A detailed description of the clinico-pathological characteristics of breast cancer cases has been reported elsewhere [31] and data on tumor size at diagnosis, nodal status and histological grade are briefly included in Table 2. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T2" position="float"><label>Table 2</label><caption><p><text><SENT sid="104" pm="."><plain>Clinicopathologic Characteristics of the 409 Breast Carcinoma and the Corresponding Univariate Analysis of death (OVS) and Reccurencea (DFS) </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th align="center" colspan="2"><text><SENT sid="105" pm="."><plain>Breast carcinoma specific OVS </plain></SENT>
</text></th><th align="center" colspan="2"><text><SENT sid="106" pm="."><plain>DFS </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left"><text><SENT sid="107" pm="."><plain>Characteristic </plain></SENT>
</text></td><td align="center"><text><SENT sid="108" pm="."><plain>% </plain></SENT>
</text></td><td align="center"><text><SENT sid="109" pm="."><plain>6-year rate </plain></SENT>
</text></td><td align="center"><text><SENT sid="110" pm="."><plain>P-value </plain></SENT>
</text></td><td align="center"><text><SENT sid="111" pm="."><plain>6-year rate </plain></SENT>
</text></td><td align="center"><text><SENT sid="112" pm="."><plain>P-value </plain></SENT>
</text></td></tr><tr><td colspan="6"><text><SENT sid="113" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="114" pm="."><plain>Clinical tumor size </plain></SENT>
</text></td><td/><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="115" pm="."><plain>T1-T2 </plain></SENT>
</text></td><td align="center"><text><SENT sid="116" pm="."><plain>67.08 </plain></SENT>
</text></td><td align="center"><text><SENT sid="117" pm="."><plain>82.85 </plain></SENT>
</text></td><td/><td align="center"><text><SENT sid="118" pm="."><plain>70 </plain></SENT>
</text></td><td/></tr><tr><td align="left"><text><SENT sid="119" pm="."><plain>T3-T4 </plain></SENT>
</text></td><td align="center"><text><SENT sid="120" pm="."><plain>32.92 </plain></SENT>
</text></td><td align="center"><text><SENT sid="121" pm="."><plain>62.86 </plain></SENT>
</text></td><td align="center"><text><SENT sid="122" pm="."><plain>&lt; 0.001 </plain></SENT>
</text></td><td align="center"><text><SENT sid="123" pm="."><plain>32.86 </plain></SENT>
</text></td><td align="center"><text><SENT sid="124" pm="."><plain>&lt; 0.000001 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="125" pm="."><plain>Lymph node statusb </plain></SENT>
</text></td><td/><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="126" pm="."><plain>N (+) </plain></SENT>
</text></td><td align="center"><text><SENT sid="127" pm="."><plain>46.72 </plain></SENT>
</text></td><td align="center"><text><SENT sid="128" pm="."><plain>84.23 </plain></SENT>
</text></td><td/><td align="center"><text><SENT sid="129" pm="."><plain>71.43 </plain></SENT>
</text></td><td/></tr><tr><td align="left"><text><SENT sid="130" pm="."><plain>N (-) </plain></SENT>
</text></td><td align="center"><text><SENT sid="131" pm="."><plain>53.28 </plain></SENT>
</text></td><td align="center"><text><SENT sid="132" pm="."><plain>68.57 </plain></SENT>
</text></td><td align="center"><text><SENT sid="133" pm="."><plain>&lt; 0.01 </plain></SENT>
</text></td><td align="center"><text><SENT sid="134" pm="."><plain>44.28 </plain></SENT>
</text></td><td align="center"><text><SENT sid="135" pm="."><plain>&lt; 0.00001 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="136" pm="."><plain>SBR grading </plain></SENT>
</text></td><td/><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="137" pm="."><plain>1-2 </plain></SENT>
</text></td><td align="center"><text><SENT sid="138" pm="."><plain>60.87 </plain></SENT>
</text></td><td align="center"><text><SENT sid="139" pm="."><plain>79.28 </plain></SENT>
</text></td><td/><td align="center"><text><SENT sid="140" pm="."><plain>69.10 </plain></SENT>
</text></td><td/></tr><tr><td align="left"><text><SENT sid="141" pm="."><plain>3 </plain></SENT>
</text></td><td align="center"><text><SENT sid="142" pm="."><plain>40.13 </plain></SENT>
</text></td><td align="center"><text><SENT sid="143" pm="."><plain>57.28 </plain></SENT>
</text></td><td align="center"><text><SENT sid="144" pm="."><plain>&lt; 0.02 </plain></SENT>
</text></td><td align="center"><text><SENT sid="145" pm="."><plain>47.80 </plain></SENT>
</text></td><td align="center"><text><SENT sid="146" pm="."><plain>&lt; 0.01 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="147" pm="."><plain>Age (yrs) </plain></SENT>
</text></td><td/><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="148" pm="."><plain>&lt; 50 </plain></SENT>
</text></td><td align="center"><text><SENT sid="149" pm="."><plain>57.32 </plain></SENT>
</text></td><td align="center"><text><SENT sid="150" pm="."><plain>78.1 </plain></SENT>
</text></td><td/><td align="center"><text><SENT sid="151" pm="."><plain>70.0 </plain></SENT>
</text></td><td/></tr><tr><td align="left"><text><SENT sid="152" pm="."><plain>≥50 </plain></SENT>
</text></td><td align="center"><text><SENT sid="153" pm="."><plain>42.68 </plain></SENT>
</text></td><td align="center"><text><SENT sid="154" pm="."><plain>75.71 </plain></SENT>
</text></td><td align="center"><text><SENT sid="155" pm="."><plain>NS </plain></SENT>
</text></td><td align="center"><text><SENT sid="156" pm="."><plain>67.2 </plain></SENT>
</text></td><td align="center"><text><SENT sid="157" pm="."><plain>NS </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="158" pm="."><plain>OVS: overall survival; DFS: disease free survival; SBR: Scarff, Bloom and Richardson; NS: not significant. </plain></SENT>
</text></p><p><text><SENT sid="159" pm="."><plain>aSix-year survival rates were estimated according to Kaplan and Meier. </plain></SENT>
<SENT sid="160" pm="."><plain>The log rank test was used to determine whether significant differences (P value) were observed between subgroups of patients. </plain></SENT>
</text></p><p><text><SENT sid="161" pm="."><plain>bDetermined based on the pathologic examination. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="162" pm="."><plain>Both patients and controls gave their written consent to participate in the study and to allow their biological samples to be genetically analyzed. </plain></SENT>
<SENT sid="163" pm="."><plain>Approval for the study was given by the National Ethical Committee. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="164" pm="."><plain>Genomic DNA Extraction </plain></SENT>
</text></title><p><text><SENT sid="165" pm="."><plain>Genomic DNA was extracted from peripheral blood leukocytes by a salting procedure [32]. </plain></SENT>
<SENT sid="166" pm="."><plain>Briefly, 10 ml of blood was mixed with triton lysis buffer (0.32 M sucrose, 1% Triton X-100, 5 mM MgCl2, H2O, 10 mM Tris-HCl, pH 7.5). </plain></SENT>
<SENT sid="167" pm="."><plain>Leukocytes were spun down and washed with H2O. </plain></SENT>
<SENT sid="168" pm="."><plain>The pellet was incubated with proteinase K at 56°C and subsequently salted out at 4°C using a substrate NaCl solution. </plain></SENT>
<SENT sid="169" pm="."><plain>Precipated proteins were removed by centrifugation. </plain></SENT>
<SENT sid="170" pm="."><plain>The DNA in supernatant fluid was precipated with ethanol. </plain></SENT>
<SENT sid="171" pm="."><plain>The DNA pellet was dissolved in 400 μl H2O. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="172" pm="."><plain>IL-8 (-251) T/A and CXCR2 (+1208) C/T genotyping </plain></SENT>
</text></title><p><text><SENT sid="173" pm="."><plain>An allele-specific polymerase chain reaction (AS-PCR) was used to detect the polymorphisms at positions -251 of IL-8 gene and +1208 of CXCR2 gene. </plain></SENT>
<SENT sid="174" pm="."><plain>For CXCR2 genotyping, 10 μl of PCR reaction mixture consisting of 50 ng of genomic DNA, 0.01 mM dNTPs, 2 mM MgCl2, 1× Taq polymerase buffer, 0.75 μM of each specific/common primer (Amersham, Paris, France), 0.2 μM of each internal control primer (see Table 3 for primer sequences) and 0.5 U of Taq DNA polymerase (Amersham, Paris, France) were employed. </plain></SENT>
<SENT sid="175" pm="."><plain>As an internal control, the Beta-globin specific primers were included in the AS-PCR (Table 2). </plain></SENT>
<SENT sid="176" pm="."><plain>First, a touch-down procedure 25 s at 95°C was carried out. </plain></SENT>
<SENT sid="177" pm="."><plain>This was followed by annealing for 45 s at temperatures decreasing from 66°C (four cycles) to 60°C (25 cycles) and an extension step at 72°C for 40 s. </plain></SENT>
<SENT sid="178" pm="."><plain>The genotypes of IL-8 (-251) T/A marker were determined as previously reported [30]. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T3" position="float"><label>Table 3</label><caption><p><text><SENT sid="179" pm="."><plain>Primer sequences used for genotyping of IL-8 (-251) T/A and CXCR2 (+1208) C/T gene polymorphisms (rs 4073 and rs 1801032) </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><text><SENT sid="180" pm="."><plain>Primer name </plain></SENT>
</text></th><th align="left"><text><SENT sid="181" pm="."><plain>Primer sequence </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left"><text><SENT sid="182" pm="."><plain>IL-8 (-251) Common </plain></SENT>
</text></td><td align="left"><text><SENT sid="183" pm="."><plain>5'-AAT ACG GAG TAT GAC GAA A-3' </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="184" pm="."><plain>IL-8 (-251) T (low expresser) </plain></SENT>
</text></td><td align="left"><text><SENT sid="185" pm="."><plain>5'-CTA GAA ATA AAA AAG CAT ACA T-3' </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="186" pm="."><plain>IL-8 (-251) A (high expresser) </plain></SENT>
</text></td><td align="left"><text><SENT sid="187" pm="."><plain>5'-CTA GAA ATA AAA AAG CAT ACA A-3' </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="188" pm="."><plain>HGH I CONTROL </plain></SENT>
</text></td><td align="left"><text><SENT sid="189" pm="."><plain>5'-GCC TTC CCA ACC ATT CCC TTA-3' </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="190" pm="."><plain>HGH II CONTROL </plain></SENT>
</text></td><td align="left"><text><SENT sid="191" pm="."><plain>5'-TCA CGG ATT TCT GTT GTG TTT-3' </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="192" pm="."><plain>CXCR2 (+1208) Common </plain></SENT>
</text></td><td align="left"><text><SENT sid="193" pm="."><plain>5'-GTC TTG TGA ATA AGC TGC TAT GA-3' </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="194" pm="."><plain>CXCR2 (+1208) C Allele </plain></SENT>
</text></td><td align="left"><text><SENT sid="195" pm="."><plain>5'-CCA TTG TGG TCA CAG GAA GC-3' </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="196" pm="."><plain>CXCR2 (+1208) T Allele </plain></SENT>
</text></td><td align="left"><text><SENT sid="197" pm="."><plain>5'-CCA TTG TGG TCA CAG GAA GT-3' </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="198" pm="."><plain>Beta Globin I </plain></SENT>
</text></td><td align="left"><text><SENT sid="199" pm="."><plain>5'-ACA CAA CTG TGT TCA CTA-3' </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="200" pm="."><plain>Beta Globin II </plain></SENT>
</text></td><td align="left"><text><SENT sid="201" pm="."><plain>5'-CAA CTT CAT CCA CGT TCA CC-3' </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="202" pm="."><plain>HGH I and II primers amplify HGH (human growth hormone) sequence. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="203" pm="."><plain>The reaction products of IL-8 and CXCR2 gene amplification were loaded onto 2% agarose gel containing ethidium bromide, electrophoresed and visualized under UV transillumination. </plain></SENT>
<SENT sid="204" pm="."><plain>To ensure quality control of all genotyping results, 25% of randomly selected samples of both cases and controls were analysed a second time, without finding any discrepancies. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="205" pm="."><plain>Statistical analyses </plain></SENT>
</text></title><p><text><SENT sid="206" pm="."><plain>The genotype and allele frequencies of IL-8 and CXCR2 were tested for the Hardy-Weinberg equilibrium for both patient and control groups using the chi-square test. </plain></SENT>
<SENT sid="207" pm="."><plain>Two-sample t tests and Chi-square tests were used to explore the bivariate association between the status of breast cancer and other covariates for continuous and categorical variables, respectively. </plain></SENT>
<SENT sid="208" pm="."><plain>Risk association between the genotypes and breast cancer susceptibility and tumours characteristics was estimated by odds ratio (OR) and 95% confidence intervals (95% CI) using multivariate logistic regression analysis. </plain></SENT>
<SENT sid="209" pm="."><plain>The model for adjusted OR included age at diagnosis, history of benign breast disease, use of oral contraceptive, and body mass index (BMI). </plain></SENT>
</text></p><p><text><SENT sid="210" pm="."><plain>Disease-free survival (DFS) was defined as the time from the date of diagnosis to the first local or distant recurrence or to last contact. </plain></SENT>
<SENT sid="211" pm="."><plain>Breast carcinoma-specific overall survival (OVS) was defined as the time from the date of diagnosis to death if the patient died from breast carcinoma or to last contact. </plain></SENT>
<SENT sid="212" pm="."><plain>Six-year survival rates were estimated, and survival curves were plotted according to Kaplan and Meier [33]. </plain></SENT>
<SENT sid="213" pm="."><plain>The differences between groups were calculated by the log-rank test [34]. </plain></SENT>
</text></p><p><text><SENT sid="214" pm="."><plain>In multivariate analysis, relative risk of recurrence or death from breast carcinoma, 95% confidence intervals, and P values for censored survival data were calculated by use of Cox proportional hazards regression Model [35]. </plain></SENT>
<SENT sid="215" pm="."><plain>All P value calculations were two-sided, and P value was considered significant at less than 0.05. </plain></SENT>
<SENT sid="216" pm="."><plain>Only clinicopathologic parameters bearing prognostic significance were included in the Cox model. </plain></SENT>
<SENT sid="217" pm="."><plain>Clinicopathological parameters were dichotomised as follows: nodal status (≥1 versus no positive lymph node), SBR (Scarff, Bloom and Richardson) tumour grade (1-2 versus 3), clinical tumour size (T1-T2 versus T3-T4). </plain></SENT>
</text></p><p><text><SENT sid="218" pm="."><plain>The statistical analysis was performed using SEM-STATISTIQUES software (centre Jean Perrin, Clermont-Ferrand, France). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec><title><text><SENT sid="219" pm="."><plain>Results </plain></SENT>
</text></title><sec><title><text><SENT sid="220" pm="."><plain>Polymorphisms in the IL-8 and CXCR2 genes as risk factors for breast carcinoma </plain></SENT>
</text></title><p><text><SENT sid="221" pm="."><plain>The breast cancer patients (n = 409) and healthy controls (n = 301) were all native Tunisian women. </plain></SENT>
<SENT sid="222" pm="."><plain>The characteristics of the healthy controls and breast cancer patients, including overage ages, body mass index (BMI), history of benign breast disease, and oral contraceptives usage were summarized in Table 1. </plain></SENT>
<SENT sid="223" pm="."><plain>There were no significant differences between cases and controls concerning age. </plain></SENT>
<SENT sid="224" pm="."><plain>However, BMI, history of benign breast disease, and oral contraceptives usage were significantly different between cases and controls after the statistical testing (see materials and methods). </plain></SENT>
<SENT sid="225" pm="."><plain>These confounding factors were adjusted in multivariate logistic regression analysis. </plain></SENT>
</text></p><p><text><SENT sid="226" pm="."><plain>The genotype distribution and allele frequencies for the IL-8 (-251) T/A and CXCR2 (+1208) C/T polymorphisms in all breast carcinoma patients and controls are presented in Table 4. </plain></SENT>
<SENT sid="227" pm="."><plain>The allele frequencies of IL-8 and CXCR2 genes were in Hardy-Weinberg equilibrium in both patients and controls (P = , P = , P = , P = respectively). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T4" position="float"><label>Table 4</label><caption><p><text><SENT sid="228" pm="."><plain>The IL-8 (-251) T/A and CXCR2 (+1208) C/T genotype distributions in Control Subjects and in Patients with Breast Carcinoma </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><text><SENT sid="229" pm="."><plain>Genotypes </plain></SENT>
</text></th><th align="center"><text><SENT sid="230" pm="."><plain>Patients (n = 409) </plain></SENT>
</text></th><th align="center"><text><SENT sid="231" pm="."><plain>Controls (n = 301) </plain></SENT>
</text></th><th align="center"><text><SENT sid="232" pm="."><plain>Crude OR (95% CI) </plain></SENT>
</text></th><th align="center"><text><SENT sid="233" pm="."><plain>P-valuea </plain></SENT>
</text></th><th align="center"><text><SENT sid="234" pm="."><plain>Adjusted OR (95% CI)b </plain></SENT>
</text></th><th align="center"><text><SENT sid="235" pm="."><plain>P-value </plain></SENT>
</text></th></tr></thead><tbody><tr><td/><td align="center"><text><SENT sid="236" pm="."><plain>n (%) </plain></SENT>
</text></td><td align="center"><text><SENT sid="237" pm="."><plain>n (%) </plain></SENT>
</text></td><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="238" pm="."><plain>IL-8 (-251)T/A </plain></SENT>
</text></td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="239" pm="."><plain>TT </plain></SENT>
</text></td><td align="center"><text><SENT sid="240" pm="."><plain>84 (20.5) </plain></SENT>
</text></td><td align="center"><text><SENT sid="241" pm="."><plain>92 (30.6) </plain></SENT>
</text></td><td align="center"><text><SENT sid="242" pm="."><plain>1 </plain></SENT>
</text></td><td/><td align="center"><text><SENT sid="243" pm="."><plain>1 </plain></SENT>
</text></td><td/></tr><tr><td align="left"><text><SENT sid="244" pm="."><plain>TA </plain></SENT>
</text></td><td align="center"><text><SENT sid="245" pm="."><plain>201 (49.2) </plain></SENT>
</text></td><td align="center"><text><SENT sid="246" pm="."><plain>138 (45.8) </plain></SENT>
</text></td><td align="center"><text><SENT sid="247" pm="."><plain>1.60 [1.09-2.34] </plain></SENT>
</text></td><td align="center"><text><SENT sid="248" pm="."><plain>0.01 </plain></SENT>
</text></td><td align="center"><text><SENT sid="249" pm="."><plain>1.71 [1.13-2.55] </plain></SENT>
</text></td><td align="center"><text><SENT sid="250" pm="."><plain>0.009 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="251" pm="."><plain>AA </plain></SENT>
</text></td><td align="center"><text><SENT sid="252" pm="."><plain>124 (30.3) </plain></SENT>
</text></td><td align="center"><text><SENT sid="253" pm="."><plain>71 (23.6) </plain></SENT>
</text></td><td align="center"><text><SENT sid="254" pm="."><plain>1.91 [1.24-2.96] </plain></SENT>
</text></td><td align="center"><text><SENT sid="255" pm="."><plain>0.002 </plain></SENT>
</text></td><td align="center"><text><SENT sid="256" pm="."><plain>2.03 [1.56-3.67] </plain></SENT>
</text></td><td align="center"><text><SENT sid="257" pm="."><plain>0.001 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="258" pm="."><plain>Alleles </plain></SENT>
</text></td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="259" pm="."><plain>T-allele </plain></SENT>
</text></td><td align="center"><text><SENT sid="260" pm="."><plain>369 (45.1) </plain></SENT>
</text></td><td align="center"><text><SENT sid="261" pm="."><plain>322 (53.5) </plain></SENT>
</text></td><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="262" pm="."><plain>A-allele </plain></SENT>
</text></td><td align="center"><text><SENT sid="263" pm="."><plain>449 (54.9) </plain></SENT>
</text></td><td align="center"><text><SENT sid="264" pm="."><plain>280 (46.5) </plain></SENT>
</text></td><td align="center"><text><SENT sid="265" pm="."><plain>1.40 [1.13-1.74] </plain></SENT>
</text></td><td align="center"><text><SENT sid="266" pm="."><plain>0.001 </plain></SENT>
</text></td><td align="center"><text><SENT sid="267" pm="."><plain>1.86 [1.79-2.45] </plain></SENT>
</text></td><td align="center"><text><SENT sid="268" pm="."><plain>0.001 </plain></SENT>
</text></td></tr><tr><td colspan="7"><text><SENT sid="269" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="270" pm="."><plain>CXCR2 (+1208)C/T </plain></SENT>
</text></td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="271" pm="."><plain>CC </plain></SENT>
</text></td><td align="center"><text><SENT sid="272" pm="."><plain>195 (46.7) </plain></SENT>
</text></td><td align="center"><text><SENT sid="273" pm="."><plain>155 (51.5) </plain></SENT>
</text></td><td align="center"><text><SENT sid="274" pm="."><plain>1 </plain></SENT>
</text></td><td/><td align="center"><text><SENT sid="275" pm="."><plain>1 </plain></SENT>
</text></td><td/></tr><tr><td align="left"><text><SENT sid="276" pm="."><plain>CT </plain></SENT>
</text></td><td align="center"><text><SENT sid="277" pm="."><plain>167 (40.8) </plain></SENT>
</text></td><td align="center"><text><SENT sid="278" pm="."><plain>128 (42.5) </plain></SENT>
</text></td><td align="center"><text><SENT sid="279" pm="."><plain>1.04 [0.75-1.43] </plain></SENT>
</text></td><td align="center"><text><SENT sid="280" pm="."><plain>0.81 </plain></SENT>
</text></td><td align="center"><text><SENT sid="281" pm="."><plain>1.31 [0.90-1.69] </plain></SENT>
</text></td><td align="center"><text><SENT sid="282" pm="."><plain>0.63 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="283" pm="."><plain>TT </plain></SENT>
</text></td><td align="center"><text><SENT sid="284" pm="."><plain>47 (11.5) </plain></SENT>
</text></td><td align="center"><text><SENT sid="285" pm="."><plain>18 (6.0) </plain></SENT>
</text></td><td align="center"><text><SENT sid="286" pm="."><plain>2.08 [1.12-3.88] </plain></SENT>
</text></td><td align="center"><text><SENT sid="287" pm="."><plain>0.01 </plain></SENT>
</text></td><td align="center"><text><SENT sid="288" pm="."><plain>2.89 [1.48-4.55] </plain></SENT>
</text></td><td align="center"><text><SENT sid="289" pm="."><plain>0.008 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="290" pm="."><plain>Alleles </plain></SENT>
</text></td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="291" pm="."><plain>C-allele </plain></SENT>
</text></td><td align="center"><text><SENT sid="292" pm="."><plain>557 (6.81) </plain></SENT>
</text></td><td align="center"><text><SENT sid="293" pm="."><plain>438 (7.28) </plain></SENT>
</text></td><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="294" pm="."><plain>T-allele </plain></SENT>
</text></td><td align="center"><text><SENT sid="295" pm="."><plain>261 (31.9) </plain></SENT>
</text></td><td align="center"><text><SENT sid="296" pm="."><plain>164 (27.2) </plain></SENT>
</text></td><td align="center"><text><SENT sid="297" pm="."><plain>1.25 [0.99-1.59] </plain></SENT>
</text></td><td align="center"><text><SENT sid="298" pm="."><plain>0.05 </plain></SENT>
</text></td><td align="center"><text><SENT sid="299" pm="."><plain>1.37 [1.09-1.88] </plain></SENT>
</text></td><td align="center"><text><SENT sid="300" pm="."><plain>0.03 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="301" pm="."><plain>a P-value determined by χ2 test. </plain></SENT>
</text></p><p><text><SENT sid="302" pm="."><plain>b ORs were adjusted for age, BMI, history of benign disease, and oral contraceptive drugs usage. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="303" pm="."><plain>A significantly higher risk for breast cancer was observed for carriers of IL-8 (-251) AA genotype (adjusted Odds Ratio (OR) = 2.03; P = 0.001) and carriers of IL-8 (-251) TA genotype (OR = 1.71; P = 0.009). </plain></SENT>
<SENT sid="304" pm="."><plain>The IL-8 (-251) A allele was significantly higher in patients compared to controls (OR = 1.86; P = 0.001). </plain></SENT>
</text></p><p><text><SENT sid="305" pm="."><plain>The genotype frequency of the CXCR2 (+1208) TT was 0.115 in patients with breast carcinoma and 0.06 in control subjects (OR = 2.89; P = 0.008). </plain></SENT>
<SENT sid="306" pm="."><plain>The CXCR2 (+1208) T allele was significantly higher in patients compared to controls (OR = 1.37; P = 0.03) (Table 4). </plain></SENT>
</text></p><p><text><SENT sid="307" pm="."><plain>Because IL-8 functionally interacts with CXCR2 we assessed the effect of multiple genotypes on breast carcinoma risk. </plain></SENT>
<SENT sid="308" pm="."><plain>Through individual investigations of genotypes, we defined IL-8 (-251) TA, IL-8 (-251) AA, and CXCR2 (+1208) TT as high-risk genotypes. </plain></SENT>
</text></p><p><text><SENT sid="309" pm="."><plain>Table 5 shows the relation between ORs and the number of high-risk genotypes. </plain></SENT>
<SENT sid="310" pm="."><plain>In controls, there were no high-risk genotypes in 26.91%, 1 in 68.44% and 2 in 4.65%. </plain></SENT>
<SENT sid="311" pm="."><plain>However, in breast cancer patients, there were no high-risk genotypes in 18.3%, 1 in 71.7% and 2 in 10.02%. </plain></SENT>
<SENT sid="312" pm="."><plain>The presence of 1 or 2 high-risk genotypes significantly increased the risk of developing breast carcinoma, with ORs of 1.63 (95% CI, 1.13 - 2.59; P = 0.01) and 4.15 (95% CI, 1.92 - 7.32; P = 0.0004), respectively, compared with the absence of the high-risk genotype. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T5" position="float"><label>Table 5</label><caption><p><text><SENT sid="313" pm="."><plain>Interaction and addictive effects of IL-8 (-251) T/A and CXCR2 (+1208) C/T polymorphisms on breast cancer risk </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><text><SENT sid="314" pm="."><plain>Genotypes </plain></SENT>
</text></th><th align="center"><text><SENT sid="315" pm="."><plain>Patients (n = 409) </plain></SENT>
</text></th><th align="center"><text><SENT sid="316" pm="."><plain>Controls (n = 301) </plain></SENT>
</text></th><th align="center"><text><SENT sid="317" pm="."><plain>Crude OR (95% CI) </plain></SENT>
</text></th><th align="center"><text><SENT sid="318" pm="."><plain>P-valuea </plain></SENT>
</text></th><th align="center"><text><SENT sid="319" pm="."><plain>Adjusted OR (95%)b </plain></SENT>
</text></th><th align="center"><text><SENT sid="320" pm="."><plain>P-value </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left"><text><SENT sid="321" pm="."><plain>IL-8 (-251)/CXCR2 (+1208) </plain></SENT>
</text></td><td align="center"><text><SENT sid="322" pm="."><plain>n % </plain></SENT>
</text></td><td align="center"><text><SENT sid="323" pm="."><plain>n % </plain></SENT>
</text></td><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="324" pm="."><plain>0 </plain></SENT>
</text></td><td align="center"><text><SENT sid="325" pm="."><plain>75 (18.34) </plain></SENT>
</text></td><td align="center"><text><SENT sid="326" pm="."><plain>81 (26.91) </plain></SENT>
</text></td><td align="center"><text><SENT sid="327" pm="."><plain>1 </plain></SENT>
</text></td><td/><td align="center"><text><SENT sid="328" pm="."><plain>1 </plain></SENT>
</text></td><td/></tr><tr><td align="left"><text><SENT sid="329" pm="."><plain>1 </plain></SENT>
</text></td><td align="center"><text><SENT sid="330" pm="."><plain>293 (71.64) </plain></SENT>
</text></td><td align="center"><text><SENT sid="331" pm="."><plain>206 (68.44) </plain></SENT>
</text></td><td align="center"><text><SENT sid="332" pm="."><plain>1.54 [1.05-2.24] </plain></SENT>
</text></td><td align="center"><text><SENT sid="333" pm="."><plain>0.01 </plain></SENT>
</text></td><td align="center"><text><SENT sid="334" pm="."><plain>1.63 [1.13-2.59] </plain></SENT>
</text></td><td align="center"><text><SENT sid="335" pm="."><plain>0.01 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="336" pm="."><plain>2 </plain></SENT>
</text></td><td align="center"><text><SENT sid="337" pm="."><plain>41 (10.02) </plain></SENT>
</text></td><td align="center"><text><SENT sid="338" pm="."><plain>14 (4.65) </plain></SENT>
</text></td><td align="center"><text><SENT sid="339" pm="."><plain>3.16 [1.52-6.64] </plain></SENT>
</text></td><td align="center"><text><SENT sid="340" pm="."><plain>0.0006 </plain></SENT>
</text></td><td align="center"><text><SENT sid="341" pm="."><plain>4.15 [1.92-7.32] </plain></SENT>
</text></td><td align="center"><text><SENT sid="342" pm="."><plain>0.0004 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="343" pm="."><plain>a P-value determined by χ2 test. </plain></SENT>
</text></p><p><text><SENT sid="344" pm="."><plain>b ORs were adjusted for age, BMI, history of benign disease, and oral contraceptive drugs usage. </plain></SENT>
</text></p><p><text><SENT sid="345" pm="."><plain>The high risk genotypes: IL-8 (-251) T/A = TA/AA; CXCR2 (+1208) C/T = TT </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag></sec><sec><title><text><SENT sid="346" pm="."><plain>Prognostic significance of polymorphism in IL-8 and CXCR2 genes </plain></SENT>
</text></title><p><text><SENT sid="347" pm="."><plain>Table 2 shows the clinicopathological characterization. </plain></SENT>
<SENT sid="348" pm="."><plain>The distribution of the clinicopathological markers was in accordance with previously reported data, indicating that our cohort was representative of breast carcinoma patients. </plain></SENT>
<SENT sid="349" pm="."><plain>Disease-free survival and breast carcinoma-specific OVS rates were estimated and compared by univariate analysis on these clinicopathological parameters. </plain></SENT>
<SENT sid="350" pm="."><plain>Significant associations were found for clinical tumor size, lymph node status, and tumor grading with DFS and OVS. </plain></SENT>
<SENT sid="351" pm="."><plain>No significant differences were observed for age. </plain></SENT>
</text></p><p><text><SENT sid="352" pm="."><plain>The distributions of IL-8 and CXCR2 polymorphisms according to the clinico- pathological indices of breast carcinoma severity are presented in Tables 6 and 7. </plain></SENT>
<SENT sid="353" pm="."><plain>A significant association between IL-8 (-251) A allele and large tumor size (T3-T4), high SBR tumor grade (grade 3), and lymph node metastases was observed (Table 6). </plain></SENT>
<SENT sid="354" pm="."><plain>In this analysis, we also observed the association of this polymorphism with the hormone status of breast carcinoma. </plain></SENT>
<SENT sid="355" pm="."><plain>Interestingly, a pronounced association was found between the IL-8 (-251) A allele and a negative hormone status (OR = 1.82; P = 0.0008). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T6" position="float"><label>Table 6</label><caption><p><text><SENT sid="356" pm="."><plain>Genotype frequencies of IL-8 (-251) T/A polymorphism in relation to pathological indices of Breast Cancer severity </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><text><SENT sid="357" pm="."><plain>Genotypes </plain></SENT>
</text></th><th align="center" colspan="2"><text><SENT sid="358" pm="."><plain>Number of patients (%) </plain></SENT>
</text></th><th align="center"><text><SENT sid="359" pm="."><plain>Crude OR (95% CI) </plain></SENT>
</text></th><th align="center"><text><SENT sid="360" pm="."><plain>P-valuea </plain></SENT>
</text></th><th align="center"><text><SENT sid="361" pm="."><plain>Adjusted OR (95% CI)b </plain></SENT>
</text></th><th align="center"><text><SENT sid="362" pm="."><plain>P-value </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left"><text><SENT sid="363" pm="."><plain>Clinical tumor size </plain></SENT>
</text></td><td align="center"><text><SENT sid="364" pm="."><plain>T1-T2 </plain></SENT>
</text></td><td align="center"><text><SENT sid="365" pm="."><plain>T3-T4 </plain></SENT>
</text></td><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="366" pm="."><plain>TT </plain></SENT>
</text></td><td align="center"><text><SENT sid="367" pm="."><plain>65 (27.08) </plain></SENT>
</text></td><td align="center"><text><SENT sid="368" pm="."><plain>37 (24.51) </plain></SENT>
</text></td><td align="center"><text><SENT sid="369" pm="."><plain>1 </plain></SENT>
</text></td><td/><td align="center"><text><SENT sid="370" pm="."><plain>1 </plain></SENT>
</text></td><td/></tr><tr><td align="left"><text><SENT sid="371" pm="."><plain>TA </plain></SENT>
</text></td><td align="center"><text><SENT sid="372" pm="."><plain>122 (50.84) </plain></SENT>
</text></td><td align="center"><text><SENT sid="373" pm="."><plain>58 (38.41) </plain></SENT>
</text></td><td align="center"><text><SENT sid="374" pm="."><plain>0.84 [0.49-1.44] </plain></SENT>
</text></td><td align="center"><text><SENT sid="375" pm="."><plain>0.48 </plain></SENT>
</text></td><td align="center"><text><SENT sid="376" pm="."><plain>0.74 [0.67-1.32] </plain></SENT>
</text></td><td align="center"><text><SENT sid="377" pm="."><plain>0.87 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="378" pm="."><plain>AA </plain></SENT>
</text></td><td align="center"><text><SENT sid="379" pm="."><plain>53 (22.08) </plain></SENT>
</text></td><td align="center"><text><SENT sid="380" pm="."><plain>56 (37.08) </plain></SENT>
</text></td><td align="center"><text><SENT sid="381" pm="."><plain>1.86 [1.03-3.35] </plain></SENT>
</text></td><td align="center"><text><SENT sid="382" pm="."><plain>0.02 </plain></SENT>
</text></td><td align="center"><text><SENT sid="383" pm="."><plain>1.79 [1.11-3.76] </plain></SENT>
</text></td><td align="center"><text><SENT sid="384" pm="."><plain>0.01 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="385" pm="."><plain>Alleles </plain></SENT>
</text></td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="386" pm="."><plain>T-allele </plain></SENT>
</text></td><td align="center"><text><SENT sid="387" pm="."><plain>252 (52.50) </plain></SENT>
</text></td><td align="center"><text><SENT sid="388" pm="."><plain>132 (43.71) </plain></SENT>
</text></td><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="389" pm="."><plain>A-allele </plain></SENT>
</text></td><td align="center"><text><SENT sid="390" pm="."><plain>228 (47.50) </plain></SENT>
</text></td><td align="center"><text><SENT sid="391" pm="."><plain>170 (56.29) </plain></SENT>
</text></td><td align="center"><text><SENT sid="392" pm="."><plain>1.42 [1.05-1.92] </plain></SENT>
</text></td><td align="center"><text><SENT sid="393" pm="."><plain>0.01 </plain></SENT>
</text></td><td align="center"><text><SENT sid="394" pm="."><plain>1.57 [1.32-2.05] </plain></SENT>
</text></td><td align="center"><text><SENT sid="395" pm="."><plain>0.01 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="396" pm="."><plain>Lymph nodes status </plain></SENT>
</text></td><td align="center"><text><SENT sid="397" pm="."><plain>Negative </plain></SENT>
</text></td><td align="center"><text><SENT sid="398" pm="."><plain>Positive </plain></SENT>
</text></td><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="399" pm="."><plain>TT </plain></SENT>
</text></td><td align="center"><text><SENT sid="400" pm="."><plain>50 (27.62) </plain></SENT>
</text></td><td align="center"><text><SENT sid="401" pm="."><plain>42 (19.91) </plain></SENT>
</text></td><td align="center"><text><SENT sid="402" pm="."><plain>1 </plain></SENT>
</text></td><td/><td align="center"><text><SENT sid="403" pm="."><plain>1 </plain></SENT>
</text></td><td/></tr><tr><td align="left"><text><SENT sid="404" pm="."><plain>TA </plain></SENT>
</text></td><td align="center"><text><SENT sid="405" pm="."><plain>92 (50.83) </plain></SENT>
</text></td><td align="center"><text><SENT sid="406" pm="."><plain>95 (45.02) </plain></SENT>
</text></td><td align="center"><text><SENT sid="407" pm="."><plain>1.46 [0.85-2.52] </plain></SENT>
</text></td><td align="center"><text><SENT sid="408" pm="."><plain>0.14 </plain></SENT>
</text></td><td align="center"><text><SENT sid="409" pm="."><plain>1.32 [0.78-2.01] </plain></SENT>
</text></td><td align="center"><text><SENT sid="410" pm="."><plain>0.21 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="411" pm="."><plain>AA </plain></SENT>
</text></td><td align="center"><text><SENT sid="412" pm="."><plain>39 (21.55) </plain></SENT>
</text></td><td align="center"><text><SENT sid="413" pm="."><plain>74 (35.07) </plain></SENT>
</text></td><td align="center"><text><SENT sid="414" pm="."><plain>2.26 [1.24-4.14] </plain></SENT>
</text></td><td align="center"><text><SENT sid="415" pm="."><plain>0.004 </plain></SENT>
</text></td><td align="center"><text><SENT sid="416" pm="."><plain>2.59 [1.47-5.32] </plain></SENT>
</text></td><td align="center"><text><SENT sid="417" pm="."><plain>0.002 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="418" pm="."><plain>Alleles </plain></SENT>
</text></td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="419" pm="."><plain>T-allele </plain></SENT>
</text></td><td align="center"><text><SENT sid="420" pm="."><plain>192 (53.04) </plain></SENT>
</text></td><td align="center"><text><SENT sid="421" pm="."><plain>179 (42.42) </plain></SENT>
</text></td><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="422" pm="."><plain>A-allele </plain></SENT>
</text></td><td align="center"><text><SENT sid="423" pm="."><plain>170 (46.96) </plain></SENT>
</text></td><td align="center"><text><SENT sid="424" pm="."><plain>243 (57.58) </plain></SENT>
</text></td><td align="center"><text><SENT sid="425" pm="."><plain>1.53 [1.14-2.05] </plain></SENT>
</text></td><td align="center"><text><SENT sid="426" pm="."><plain>0.002 </plain></SENT>
</text></td><td align="center"><text><SENT sid="427" pm="."><plain>1.58 [1.28-2.24] </plain></SENT>
</text></td><td align="center"><text><SENT sid="428" pm="."><plain>0.001 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="429" pm="."><plain>SBR grading </plain></SENT>
</text></td><td align="center"><text><SENT sid="430" pm="."><plain>1-2 </plain></SENT>
</text></td><td align="center"><text><SENT sid="431" pm="."><plain>3 </plain></SENT>
</text></td><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="432" pm="."><plain>TT </plain></SENT>
</text></td><td align="center"><text><SENT sid="433" pm="."><plain>66 (32.19) </plain></SENT>
</text></td><td align="center"><text><SENT sid="434" pm="."><plain>46 (28.22) </plain></SENT>
</text></td><td align="center"><text><SENT sid="435" pm="."><plain>1 </plain></SENT>
</text></td><td/><td align="center"><text><SENT sid="436" pm="."><plain>1 </plain></SENT>
</text></td><td/></tr><tr><td align="left"><text><SENT sid="437" pm="."><plain>TA </plain></SENT>
</text></td><td align="center"><text><SENT sid="438" pm="."><plain>111 (54.15) </plain></SENT>
</text></td><td align="center"><text><SENT sid="439" pm="."><plain>67 (41.11) </plain></SENT>
</text></td><td align="center"><text><SENT sid="440" pm="."><plain>0.87 [0.52-1.45] </plain></SENT>
</text></td><td align="center"><text><SENT sid="441" pm="."><plain>0.55 </plain></SENT>
</text></td><td align="center"><text><SENT sid="442" pm="."><plain>0.91 [0.58-1.49] </plain></SENT>
</text></td><td align="center"><text><SENT sid="443" pm="."><plain>0.34 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="444" pm="."><plain>AA </plain></SENT>
</text></td><td align="center"><text><SENT sid="445" pm="."><plain>28 (13.66) </plain></SENT>
</text></td><td align="center"><text><SENT sid="446" pm="."><plain>50 (30.67) </plain></SENT>
</text></td><td align="center"><text><SENT sid="447" pm="."><plain>2.56 [1.35-4.87] </plain></SENT>
</text></td><td align="center"><text><SENT sid="448" pm="."><plain>0.001 </plain></SENT>
</text></td><td align="center"><text><SENT sid="449" pm="."><plain>2.69 [1.52-5.24] </plain></SENT>
</text></td><td align="center"><text><SENT sid="450" pm="."><plain>0.0009 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="451" pm="."><plain>Alleles </plain></SENT>
</text></td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="452" pm="."><plain>T-allele </plain></SENT>
</text></td><td align="center"><text><SENT sid="453" pm="."><plain>243 (59.27) </plain></SENT>
</text></td><td align="center"><text><SENT sid="454" pm="."><plain>159 (48.77) </plain></SENT>
</text></td><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="455" pm="."><plain>A-allele </plain></SENT>
</text></td><td align="center"><text><SENT sid="456" pm="."><plain>167 (40.73) </plain></SENT>
</text></td><td align="center"><text><SENT sid="457" pm="."><plain>167 (51.23) </plain></SENT>
</text></td><td align="center"><text><SENT sid="458" pm="."><plain>1.53 [1.13-2.07] </plain></SENT>
</text></td><td align="center"><text><SENT sid="459" pm="."><plain>0.004 </plain></SENT>
</text></td><td align="center"><text><SENT sid="460" pm="."><plain>1.66 [1.38-2.79] </plain></SENT>
</text></td><td align="center"><text><SENT sid="461" pm="."><plain>0.002 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="462" pm="."><plain>Estrogen receptor status </plain></SENT>
</text></td><td align="center"><text><SENT sid="463" pm="."><plain>Negative </plain></SENT>
</text></td><td align="center"><text><SENT sid="464" pm="."><plain>Positive </plain></SENT>
</text></td><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="465" pm="."><plain>TT </plain></SENT>
</text></td><td align="center"><text><SENT sid="466" pm="."><plain>41 (23.7) </plain></SENT>
</text></td><td align="center"><text><SENT sid="467" pm="."><plain>51 (41.13) </plain></SENT>
</text></td><td align="center"><text><SENT sid="468" pm="."><plain>1 </plain></SENT>
</text></td><td/><td align="center"><text><SENT sid="469" pm="."><plain>1 </plain></SENT>
</text></td><td/></tr><tr><td align="left"><text><SENT sid="470" pm="."><plain>TA </plain></SENT>
</text></td><td align="center"><text><SENT sid="471" pm="."><plain>75 (43.35) </plain></SENT>
</text></td><td align="center"><text><SENT sid="472" pm="."><plain>44 (35.48) </plain></SENT>
</text></td><td align="center"><text><SENT sid="473" pm="."><plain>2.12 [1.17-3.84] </plain></SENT>
</text></td><td align="center"><text><SENT sid="474" pm="."><plain>0.007 </plain></SENT>
</text></td><td align="center"><text><SENT sid="475" pm="."><plain>2.01 [1.32-3.76] </plain></SENT>
</text></td><td align="center"><text><SENT sid="476" pm="."><plain>0.006 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="477" pm="."><plain>AA </plain></SENT>
</text></td><td align="center"><text><SENT sid="478" pm="."><plain>57 (32.95) </plain></SENT>
</text></td><td align="center"><text><SENT sid="479" pm="."><plain>29 (23.39) </plain></SENT>
</text></td><td align="center"><text><SENT sid="480" pm="."><plain>2.44 [1.28-4.70] </plain></SENT>
</text></td><td align="center"><text><SENT sid="481" pm="."><plain>0.003 </plain></SENT>
</text></td><td align="center"><text><SENT sid="482" pm="."><plain>2.56 [1.68-4.96] </plain></SENT>
</text></td><td align="center"><text><SENT sid="483" pm="."><plain>0.001 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="484" pm="."><plain>Alleles </plain></SENT>
</text></td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="485" pm="."><plain>T-allele </plain></SENT>
</text></td><td align="center"><text><SENT sid="486" pm="."><plain>157 (45.38) </plain></SENT>
</text></td><td align="center"><text><SENT sid="487" pm="."><plain>146 (58.87) </plain></SENT>
</text></td><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="488" pm="."><plain>A-allele </plain></SENT>
</text></td><td align="center"><text><SENT sid="489" pm="."><plain>189 (54.62) </plain></SENT>
</text></td><td align="center"><text><SENT sid="490" pm="."><plain>102 (41.13) </plain></SENT>
</text></td><td align="center"><text><SENT sid="491" pm="."><plain>1.72 [1.22-2.48] </plain></SENT>
</text></td><td align="center"><text><SENT sid="492" pm="."><plain>0.001 </plain></SENT>
</text></td><td align="center"><text><SENT sid="493" pm="."><plain>1.82 [1.96-2.78] </plain></SENT>
</text></td><td align="center"><text><SENT sid="494" pm="."><plain>0.0008 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="495" pm="."><plain>a P-value determined by χ2 test. </plain></SENT>
</text></p><p><text><SENT sid="496" pm="."><plain>b ORs were adjusted for age, BMI, history of benign disease, and oral contraceptive drugs usage. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="497" pm="."><plain>Furthermore, the frequency of the CXCR2 (+1208) T allele was significantly higher in patients with a large tumor size (OR = 1.98; P = 0.0001), with high SBR tumor grade (grade 3) (OR = 1.67; P = 0.01), and with lymph node metastases (OR = 1.83; P = 0.0008). </plain></SENT>
<SENT sid="498" pm="."><plain>Taken together, these results suggest that the (-251) A allele of the IL-8 gene and the (+1208) T allele of the CXCR2 gene are associated with the aggressive forms of breast carcinoma. </plain></SENT>
<SENT sid="499" pm="."><plain>No association was found between CXCR2 gene polymorphism and the hormone status of breast cancer patients (Table 7). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T7" position="float"><label>Table 7</label><caption><p><text><SENT sid="500" pm="."><plain>Genotype frequencies of CXCR2 (+1208) C/T polymorphism in relation to pathological indices of Breast Cancer severity </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><text><SENT sid="501" pm="."><plain>Genotypes </plain></SENT>
</text></th><th align="center" colspan="2"><text><SENT sid="502" pm="."><plain>Number of patients (%) </plain></SENT>
</text></th><th align="center"><text><SENT sid="503" pm="."><plain>Crude OR (95% CI) </plain></SENT>
</text></th><th align="center"><text><SENT sid="504" pm="."><plain>P-valuea </plain></SENT>
</text></th><th align="center"><text><SENT sid="505" pm="."><plain>Adjusted OR (95% CI)b </plain></SENT>
</text></th><th align="center"><text><SENT sid="506" pm="."><plain>P-value </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left"><text><SENT sid="507" pm="."><plain>Clinical tumor size </plain></SENT>
</text></td><td align="center"><text><SENT sid="508" pm="."><plain>T1-T2 </plain></SENT>
</text></td><td align="center"><text><SENT sid="509" pm="."><plain>T3-T4 </plain></SENT>
</text></td><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="510" pm="."><plain>CC </plain></SENT>
</text></td><td align="center"><text><SENT sid="511" pm="."><plain>117 (48.75) </plain></SENT>
</text></td><td align="center"><text><SENT sid="512" pm="."><plain>51 (33.55) </plain></SENT>
</text></td><td align="center"><text><SENT sid="513" pm="."><plain>1 </plain></SENT>
</text></td><td/><td align="center"><text><SENT sid="514" pm="."><plain>1 </plain></SENT>
</text></td><td/></tr><tr><td align="left"><text><SENT sid="515" pm="."><plain>CT </plain></SENT>
</text></td><td align="center"><text><SENT sid="516" pm="."><plain>89 (37.08) </plain></SENT>
</text></td><td align="center"><text><SENT sid="517" pm="."><plain>62 (40.79) </plain></SENT>
</text></td><td align="center"><text><SENT sid="518" pm="."><plain>1.60 [0.98-2.61] </plain></SENT>
</text></td><td align="center"><text><SENT sid="519" pm="."><plain>0.04 </plain></SENT>
</text></td><td align="center"><text><SENT sid="520" pm="."><plain>1.73 [1.01-2.76] </plain></SENT>
</text></td><td align="center"><text><SENT sid="521" pm="."><plain>0.03 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="522" pm="."><plain>TT </plain></SENT>
</text></td><td align="center"><text><SENT sid="523" pm="."><plain>34 (14.17) </plain></SENT>
</text></td><td align="center"><text><SENT sid="524" pm="."><plain>39 (25.66) </plain></SENT>
</text></td><td align="center"><text><SENT sid="525" pm="."><plain>2.63 [1.44-4.82] </plain></SENT>
</text></td><td align="center"><text><SENT sid="526" pm="."><plain>0.0006 </plain></SENT>
</text></td><td align="center"><text><SENT sid="527" pm="."><plain>2.89 [1.64-5.06] </plain></SENT>
</text></td><td align="center"><text><SENT sid="528" pm="."><plain>0.0004 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="529" pm="."><plain>Alleles </plain></SENT>
</text></td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="530" pm="."><plain>C-allele </plain></SENT>
</text></td><td align="center"><text><SENT sid="531" pm="."><plain>323 (67.29) </plain></SENT>
</text></td><td align="center"><text><SENT sid="532" pm="."><plain>164 (53.95) </plain></SENT>
</text></td><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="533" pm="."><plain>T-allele </plain></SENT>
</text></td><td align="center"><text><SENT sid="534" pm="."><plain>157 (32.71) </plain></SENT>
</text></td><td align="center"><text><SENT sid="535" pm="."><plain>140 (46.05) </plain></SENT>
</text></td><td align="center"><text><SENT sid="536" pm="."><plain>1.76 [1.29-2.39] </plain></SENT>
</text></td><td align="center"><text><SENT sid="537" pm="."><plain>0.0001 </plain></SENT>
</text></td><td align="center"><text><SENT sid="538" pm="."><plain>1.98 [1.47-2.56] </plain></SENT>
</text></td><td align="center"><text><SENT sid="539" pm="."><plain>0.0001 </plain></SENT>
</text></td></tr><tr><td colspan="7"><text><SENT sid="540" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="541" pm="."><plain>Lymph nodes status </plain></SENT>
</text></td><td align="center"><text><SENT sid="542" pm="."><plain>Negative </plain></SENT>
</text></td><td align="center"><text><SENT sid="543" pm="."><plain>Positive </plain></SENT>
</text></td><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="544" pm="."><plain>CC </plain></SENT>
</text></td><td align="center"><text><SENT sid="545" pm="."><plain>94 (51.93) </plain></SENT>
</text></td><td align="center"><text><SENT sid="546" pm="."><plain>81 (38.39) </plain></SENT>
</text></td><td align="center"><text><SENT sid="547" pm="."><plain>1 </plain></SENT>
</text></td><td/><td align="center"><text><SENT sid="548" pm="."><plain>1 </plain></SENT>
</text></td><td/></tr><tr><td align="left"><text><SENT sid="549" pm="."><plain>CT </plain></SENT>
</text></td><td align="center"><text><SENT sid="550" pm="."><plain>69 (38.12) </plain></SENT>
</text></td><td align="center"><text><SENT sid="551" pm="."><plain>89 (42.18) </plain></SENT>
</text></td><td align="center"><text><SENT sid="552" pm="."><plain>1.50 [0.95-2.36] </plain></SENT>
</text></td><td align="center"><text><SENT sid="553" pm="."><plain>0.06 </plain></SENT>
</text></td><td align="center"><text><SENT sid="554" pm="."><plain>1.45 [0.98-2.27] </plain></SENT>
</text></td><td align="center"><text><SENT sid="555" pm="."><plain>0.07 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="556" pm="."><plain>TT </plain></SENT>
</text></td><td align="center"><text><SENT sid="557" pm="."><plain>18 (9.95) </plain></SENT>
</text></td><td align="center"><text><SENT sid="558" pm="."><plain>41 (19.43) </plain></SENT>
</text></td><td align="center"><text><SENT sid="559" pm="."><plain>2.64 [1.35-5.21] </plain></SENT>
</text></td><td align="center"><text><SENT sid="560" pm="."><plain>0.002 </plain></SENT>
</text></td><td align="center"><text><SENT sid="561" pm="."><plain>2.72 [1.44-5.43] </plain></SENT>
</text></td><td align="center"><text><SENT sid="562" pm="."><plain>0.001 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="563" pm="."><plain>Alleles </plain></SENT>
</text></td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="564" pm="."><plain>C-allele </plain></SENT>
</text></td><td align="center"><text><SENT sid="565" pm="."><plain>257 (70.99) </plain></SENT>
</text></td><td align="center"><text><SENT sid="566" pm="."><plain>251 (59.48) </plain></SENT>
</text></td><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="567" pm="."><plain>T-allele </plain></SENT>
</text></td><td align="center"><text><SENT sid="568" pm="."><plain>105 (29.01) </plain></SENT>
</text></td><td align="center"><text><SENT sid="569" pm="."><plain>171 (40.52) </plain></SENT>
</text></td><td align="center"><text><SENT sid="570" pm="."><plain>1.67 [1.22-2.27] </plain></SENT>
</text></td><td align="center"><text><SENT sid="571" pm="."><plain>0.0007 </plain></SENT>
</text></td><td align="center"><text><SENT sid="572" pm="."><plain>1.83 [1.32-2.46] </plain></SENT>
</text></td><td align="center"><text><SENT sid="573" pm="."><plain>0.0008 </plain></SENT>
</text></td></tr><tr><td colspan="7"><text><SENT sid="574" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="575" pm="."><plain>SBR grading </plain></SENT>
</text></td><td align="center"><text><SENT sid="576" pm="."><plain>1-2 </plain></SENT>
</text></td><td align="center"><text><SENT sid="577" pm="."><plain>3 </plain></SENT>
</text></td><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="578" pm="."><plain>CC </plain></SENT>
</text></td><td align="center"><text><SENT sid="579" pm="."><plain>91 (44.39) </plain></SENT>
</text></td><td align="center"><text><SENT sid="580" pm="."><plain>63 (38.18) </plain></SENT>
</text></td><td align="center"><text><SENT sid="581" pm="."><plain>1 </plain></SENT>
</text></td><td/><td align="center"><text><SENT sid="582" pm="."><plain>1 </plain></SENT>
</text></td><td/></tr><tr><td align="left"><text><SENT sid="583" pm="."><plain>CT </plain></SENT>
</text></td><td align="center"><text><SENT sid="584" pm="."><plain>85 (41.46) </plain></SENT>
</text></td><td align="center"><text><SENT sid="585" pm="."><plain>64 (38.78) </plain></SENT>
</text></td><td align="center"><text><SENT sid="586" pm="."><plain>1.09 [0.67-1.76] </plain></SENT>
</text></td><td align="center"><text><SENT sid="587" pm="."><plain>0.71 </plain></SENT>
</text></td><td align="center"><text><SENT sid="588" pm="."><plain>1.12 [0.78-1.89] </plain></SENT>
</text></td><td align="center"><text><SENT sid="589" pm="."><plain>0.65 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="590" pm="."><plain>TT </plain></SENT>
</text></td><td align="center"><text><SENT sid="591" pm="."><plain>29 (14.15) </plain></SENT>
</text></td><td align="center"><text><SENT sid="592" pm="."><plain>38 (23.03) </plain></SENT>
</text></td><td align="center"><text><SENT sid="593" pm="."><plain>1.89 [1.02-3.53] </plain></SENT>
</text></td><td align="center"><text><SENT sid="594" pm="."><plain>0.03 </plain></SENT>
</text></td><td align="center"><text><SENT sid="595" pm="."><plain>1.98 [1.15-3.79] </plain></SENT>
</text></td><td align="center"><text><SENT sid="596" pm="."><plain>0.02 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="597" pm="."><plain>Alleles </plain></SENT>
</text></td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="598" pm="."><plain>C-allele </plain></SENT>
</text></td><td align="center"><text><SENT sid="599" pm="."><plain>267 (65.12) </plain></SENT>
</text></td><td align="center"><text><SENT sid="600" pm="."><plain>190 (57.58) </plain></SENT>
</text></td><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="601" pm="."><plain>T-allele </plain></SENT>
</text></td><td align="center"><text><SENT sid="602" pm="."><plain>143 (34.88) </plain></SENT>
</text></td><td align="center"><text><SENT sid="603" pm="."><plain>140 (42.42) </plain></SENT>
</text></td><td align="center"><text><SENT sid="604" pm="."><plain>1.38 [1.01-1.87] </plain></SENT>
</text></td><td align="center"><text><SENT sid="605" pm="."><plain>0.03 </plain></SENT>
</text></td><td align="center"><text><SENT sid="606" pm="."><plain>1.67 [1.08-2.03] </plain></SENT>
</text></td><td align="center"><text><SENT sid="607" pm="."><plain>0.01 </plain></SENT>
</text></td></tr><tr><td colspan="7"><text><SENT sid="608" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="609" pm="."><plain>Estrogen receptor status </plain></SENT>
</text></td><td align="center"><text><SENT sid="610" pm="."><plain>Positive </plain></SENT>
</text></td><td align="center"><text><SENT sid="611" pm="."><plain>Negative </plain></SENT>
</text></td><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="612" pm="."><plain>CC </plain></SENT>
</text></td><td align="center"><text><SENT sid="613" pm="."><plain>50 (30.87) </plain></SENT>
</text></td><td align="center"><text><SENT sid="614" pm="."><plain>48 (33.33) </plain></SENT>
</text></td><td align="center"><text><SENT sid="615" pm="."><plain>1 </plain></SENT>
</text></td><td/><td align="center"><text><SENT sid="616" pm="."><plain>1 </plain></SENT>
</text></td><td/></tr><tr><td align="left"><text><SENT sid="617" pm="."><plain>CT </plain></SENT>
</text></td><td align="center"><text><SENT sid="618" pm="."><plain>76 (46.91) </plain></SENT>
</text></td><td align="center"><text><SENT sid="619" pm="."><plain>60 (41.67) </plain></SENT>
</text></td><td align="center"><text><SENT sid="620" pm="."><plain>1.22 [0.70-2.12] </plain></SENT>
</text></td><td align="center"><text><SENT sid="621" pm="."><plain>0.46 </plain></SENT>
</text></td><td align="center"><text><SENT sid="622" pm="."><plain>1.34 [0.78-2.34] </plain></SENT>
</text></td><td align="center"><text><SENT sid="623" pm="."><plain>0.35 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="624" pm="."><plain>TT </plain></SENT>
</text></td><td align="center"><text><SENT sid="625" pm="."><plain>36 (22.22) </plain></SENT>
</text></td><td align="center"><text><SENT sid="626" pm="."><plain>36 (25.00) </plain></SENT>
</text></td><td align="center"><text><SENT sid="627" pm="."><plain>0.96 [0.50-1.85] </plain></SENT>
</text></td><td align="center"><text><SENT sid="628" pm="."><plain>0.89 </plain></SENT>
</text></td><td align="center"><text><SENT sid="629" pm="."><plain>0.87 [0.54-1.89] </plain></SENT>
</text></td><td align="center"><text><SENT sid="630" pm="."><plain>0.85 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="631" pm="."><plain>Alleles </plain></SENT>
</text></td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="632" pm="."><plain>C-allele </plain></SENT>
</text></td><td align="center"><text><SENT sid="633" pm="."><plain>176 (54.32) </plain></SENT>
</text></td><td align="center"><text><SENT sid="634" pm="."><plain>156 (54.17) </plain></SENT>
</text></td><td/><td/><td/><td/></tr><tr><td align="left"><text><SENT sid="635" pm="."><plain>T-allele </plain></SENT>
</text></td><td align="center"><text><SENT sid="636" pm="."><plain>148 (45.68) </plain></SENT>
</text></td><td align="center"><text><SENT sid="637" pm="."><plain>132 (45.83) </plain></SENT>
</text></td><td align="center"><text><SENT sid="638" pm="."><plain>0.99 [0.71-1.38] </plain></SENT>
</text></td><td align="center"><text><SENT sid="639" pm="."><plain>0.96 </plain></SENT>
</text></td><td align="center"><text><SENT sid="640" pm="."><plain>0.95 [0.66-1.27] </plain></SENT>
</text></td><td align="center"><text><SENT sid="641" pm="."><plain>0.87 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="642" pm="."><plain>a P-value determined by χ2 test. </plain></SENT>
</text></p><p><text><SENT sid="643" pm="."><plain>b ORs were adjusted for age, BMI, history of benign disease, and oral contraceptive drugs usage. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="644" pm="."><plain>When the relationship between the distribution of IL-8 and CXCR2 genotypes in all patients and the survival (OVS and DFS) was tested, significant differences were observed between the OVS and the DFS Kaplan-Meier survival curves for the different polymorphisms. </plain></SENT>
</text></p><p><text><SENT sid="645" pm="."><plain>The breast carcinoma-specific OVS was significantly shorter among patients carrying the IL-8 (-251) A allele (Figure 1A). </plain></SENT>
<SENT sid="646" pm="."><plain>The estimated 3- and 6-year breast carcinoma-specific OVS rates for the group of patients carrying or not carrying the IL-8 (-251) A allele were respectively 91.4 and 77.1% versus 75.7 and 45.7% (log rank test, P &lt; 0.002). </plain></SENT>
<SENT sid="647" pm="."><plain>The estimated 3- and 6-year DFS rates in the group of patients with IL-8 (-251) A allele were 81.4% and 50% versus 95.7% and 88.5% in the group of patients without the IL-8 (-251) A allele (log rank test, P &lt; 0.001). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F1" position="float"><label>Figure 1</label><caption><p><text><SENT sid="648" pm="."><plain>Breast carcinoma-specific overall survival (A) and disease-free survival (B) of 409 breast carcinoma patients according to the presence or absence of IL-8 (-251) A allele (P denotes the log-rank test value). </plain></SENT>
</text></p></caption><graphic xlink:href="1471-2407-10-283-1"/></fig></SecTag><p><text><SENT sid="649" pm="."><plain>As shown in Figure 2, the breast carcinoma specific OVS and DFS were significantly shorter in the group of patients carrying CXCR2 (+1208) T allele. </plain></SENT>
<SENT sid="650" pm="."><plain>The estimated 3- and 6-year breast carcinoma OVS rate in the group of patients carrying CXCR2 (+1208) T allele were, respectively, 87.1 and 65.7% versus 95.7% and 90% for those not carrying the (+1208) T allele (log rank test, P &lt; 0.001). </plain></SENT>
<SENT sid="651" pm="."><plain>The estimated 3- and 6-year DFS rates in the group of patients with CXCR2 (+1208) T allele were 74.3% and 50% versus 90% and 61.4% in the group of patients without the CXCR2 (+1208) T allele (log rank test, P &lt; 0.01). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F2" position="float"><label>Figure 2</label><caption><p><text><SENT sid="652" pm="."><plain>Breast carcinoma-specific overall survival (C) and disease-free survival (D) of 409 breast carcinoma patients according to the presence or absence of CXCR2 (+1208) T allele (P denotes the log-rank test value). </plain></SENT>
</text></p></caption><graphic xlink:href="1471-2407-10-283-2"/></fig></SecTag><p><text><SENT sid="653" pm="."><plain>Multivariate analyses were undertaken to evaluate the importance of IL-8 and CXCR2 markers in the recurrence risk and death compared with the clinicopathological parameters. </plain></SENT>
<SENT sid="654" pm="."><plain>Introducing the genetic and the clinicopathological parameters bearing prognostic significance we tested the Cox model. </plain></SENT>
<SENT sid="655" pm="."><plain>No genetic and clinicopathological parameters were selected for OVS and DFS. </plain></SENT>
</text></p><p><text><SENT sid="656" pm="."><plain>Further analyses were conducted to explore whether combined high-risk genotypes of the IL-8 and CXCR2 genes were associated with clinicopathological indices and survival among patients. </plain></SENT>
<SENT sid="657" pm="."><plain>No additional effect was found between the presence of more than one high-risk genotype and indices of an aggressive form of breast carcinoma (nodal status, SBR, tumor grade) or OVS and DFS (data not shown). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec><title><text><SENT sid="658" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="659" pm="."><plain>The ELR+ CXC chemokines play an important role in tumor growth and progression in a number of tumor model systems. </plain></SENT>
<SENT sid="660" pm="."><plain>IL-8/CXCL8 was the first described angiogenic, mitogenic, and motogenic chemokine in various cancer models and is the prototype of ELR+ CXC chemokines [8,10-13]. </plain></SENT>
<SENT sid="661" pm="."><plain>This chemokine was initially discovered on the basis of its ability to induce mobilization of neutrophils and lymphocytes in vivo [9]. </plain></SENT>
<SENT sid="662" pm="."><plain>Like the basic fibroblast growth factor (bFGF) and the vascular endothelial growth factor (VEGF), it is a strong angiogenesis inducer. </plain></SENT>
<SENT sid="663" pm="."><plain>IL-8 mediates endothelial cell chemotaxis and proliferation in vitro and in vivo [36]. </plain></SENT>
</text></p><p><text><SENT sid="664" pm="."><plain>The fact that all ELR+CXC chemokines mediate angiogenesis highlights the importance of identifying a common receptor that mediates their biological functions in promoting angiogenesis. </plain></SENT>
<SENT sid="665" pm="."><plain>The candidate CXC chemokine receptors are CXCR1 and CXCR2. </plain></SENT>
<SENT sid="666" pm="."><plain>Only CXCL-8/IL-8 and CXCL-6 specifically bind to CXCR1 whereas all ELR+CXC chemokines bind to CXCR2. </plain></SENT>
<SENT sid="667" pm="."><plain>There is evidence that CXCR2 is implicated in the angiogenic activity of ELR+ CXC chemokines [18,36]. </plain></SENT>
</text></p><p><text><SENT sid="668" pm="."><plain>In recent years, several studies have shown that IL-8 and CXCR2 are overexpressed in a range of human cancers including renal, prostate, pancreatic, colon, nasopharyngeal, and gastric cancers [37-41]. </plain></SENT>
<SENT sid="669" pm="."><plain>IL-8 and its receptors were detected on breast tumor cells and endothelial cells of tumor vessels [19-21]. </plain></SENT>
<SENT sid="670" pm="."><plain>In addition, IL-8 levels are significantly higher in breast cancer patients compared with healthy controls [42]. </plain></SENT>
<SENT sid="671" pm="."><plain>Ben-Baruch et al have demonstrated that, aside the role of IL-8 and CXCR2 in mediating the recruitment of the tumor-infiltrating leucocytes to tumor site, their expression may also affect neoplastic proliferation and metastasis [43]. </plain></SENT>
</text></p><p><text><SENT sid="672" pm="."><plain>IL-8 and CXCR2 overexpression may present a risk factor in the development and progression of solid tumors. </plain></SENT>
<SENT sid="673" pm="."><plain>Several polymorphisms have been identified in IL-8 and CXCR2 genes. </plain></SENT>
<SENT sid="674" pm="."><plain>Among these, IL-8 (-251) T/A polymorphism exerts one of the greatest influences on IL-8 production. </plain></SENT>
<SENT sid="675" pm="."><plain>Polymorphism +1208 C/T of the CXCR2 gene is implicated in the susceptibility to and the pathogenesis of chronic inflammatory diseases [28,29]. </plain></SENT>
</text></p><p><text><SENT sid="676" pm="."><plain>Recently, we have showed that IL-8 (-251) T/A polymorphism may be a genetic risk factor for breast cancer onset and severity in the Tunisian population [30]. </plain></SENT>
<SENT sid="677" pm="."><plain>Our current study aims to confirm these results in a larger cohort and to determine whether there is any association between the genetic polymorphism of the CXCR2 and both individual susceptibility to and prognosis of breast carcinoma. </plain></SENT>
<SENT sid="678" pm="."><plain>Based on the intertwined and interactive roles that IL-8 and CXCR2 play at the molecular level in the angiogenic pathway, we further hypothesized a priori that the joint effect of genetic variants in these angiogenesis regulators may increase breast cancer risk. </plain></SENT>
</text></p><p><text><SENT sid="679" pm="."><plain>In the present study, the comparison of genotype frequencies of IL-8 for breast carcinoma patients and control subjects indicates an increase of IL-8 (-251) TA and AA genotypes. </plain></SENT>
<SENT sid="680" pm="."><plain>Consequently, the IL-8 (-251) A allele frequency was found to be significantly higher in patients compared with controls. </plain></SENT>
<SENT sid="681" pm="."><plain>These results confirmed our previous findings in a smaller subset of cases and controls [31]. </plain></SENT>
</text></p><p><text><SENT sid="682" pm="."><plain>CXCR2 genotype analysis revealed that carriers of CXCR2 (+1208) TT homozygous genotype are significantly over-represented among breast cancer cases (OR = 2.08; P = 0.01). </plain></SENT>
<SENT sid="683" pm="."><plain>Despite the great interest in CXCR2 biological properties, little is known about the functional importance of single nucleotide polymorphisms in its gene. </plain></SENT>
<SENT sid="684" pm="."><plain>This result indicates that CXCR2 gene polymorphism could be considered as a susceptibility gene in breast cancer development. </plain></SENT>
</text></p><p><text><SENT sid="685" pm="."><plain>These findings suggested that individual genetic polymorphisms of IL-8 and CXCR2 were associated with breast carcinoma risk. </plain></SENT>
<SENT sid="686" pm="."><plain>However, the combination of these genotypes showed a marked association with breast carcinoma risk. </plain></SENT>
<SENT sid="687" pm="."><plain>We defined the TA and AA genotypes of the IL-8 gene and the TT genotype of the CXCR2 gene as high-risk genotypes according to the individual genotype analysis. </plain></SENT>
<SENT sid="688" pm="."><plain>Breast carcinoma risk significantly increased according to the number of high-risk genotypes. </plain></SENT>
<SENT sid="689" pm="."><plain>There was a 63% increase in breast cancer (OR = 1.63; P = 0.01) for the presence of one high-risk genotype. </plain></SENT>
<SENT sid="690" pm="."><plain>The risk was 4.15 (P = 0.0004) for individuals with two high-risk genotypes. </plain></SENT>
<SENT sid="691" pm="."><plain>These data, taken together, suggest that there is evidence of a gene-dosage effect. </plain></SENT>
</text></p><p><text><SENT sid="692" pm="."><plain>The assessment of the prognostic value of IL-8 genetic marker in breast carcinoma confirmed the results of our previous study and indicated that IL-8 (-251) A allele is highly associated with aggressive forms of breast carcinoma as defined by large tumor size, high grade and lymph node metastases. </plain></SENT>
<SENT sid="693" pm="."><plain>In the current study, we also examined for the first time the relationship between IL-8 (-251) T/A polymorphism and the hormonal status. </plain></SENT>
<SENT sid="694" pm="."><plain>Interestingly, we observed a significant association between IL-8 (-251) A allele and a negative hormonal status (P = 0.0008). </plain></SENT>
</text></p><p><text><SENT sid="695" pm="."><plain>Furthermore, we investigated the association of the CXCR2 (+1208) C/T polymorphism with markers of tumor progression. </plain></SENT>
<SENT sid="696" pm="."><plain>Our results showed a significant association between CXCR2 (+1208) T allele and a large tumor size (P = 0.0001), high SBR tumor grade (P = 0.01), and lymph node metastases (P = 0.0008). </plain></SENT>
<SENT sid="697" pm="."><plain>More interestingly, we showed that IL-8 (-251) A and CXCR2 (+1208) T alleles were associated with a shorter overall survival and disease-free survival and, therefore, with a poor prognosis in breast carcinoma. </plain></SENT>
</text></p><p><text><SENT sid="698" pm="."><plain>Given the importance of IL-8 and CXCR2 in angiogenesis, we investigated the relationship between polymorphisms -251 T/A in IL-8 gene and (+1208) C/T in CXCR2 gene and breast carcinoma. </plain></SENT>
<SENT sid="699" pm="."><plain>The results show that these polymorphisms may be related to breast carcinoma development and progression. </plain></SENT>
</text></p><p><text><SENT sid="700" pm="."><plain>In agreement with our findings, several studies reported a relationship between IL-8 (-251) T/A and CXCR2 (+1208) C/T genes polymorphisms and human cancer. IL-8 (-251) A allele, which resulted in higher IL-8 secretion was associated with an increased risk and poor prognosis of colorectal cancer, prostate cancer, and gastric cancer [24-26,44]. </plain></SENT>
<SENT sid="701" pm="."><plain>Similarly, we reported in a previous study that IL-8 (-251) A allele held a higher risk of nasopharyngeal carcinoma and was highly associated with aggressive forms and poor prognosis [27]. </plain></SENT>
<SENT sid="702" pm="."><plain>Regarding breast carcinoma, the current study confirmed our previous results obtained in a smaller cohort and is also in agreement with Kamali-Sarvestani et al. who reported that IL-8 (-251) A allele carriers had a significantly higher risk of breast carcinoma than non carriers in the Iranian population [45]. </plain></SENT>
</text></p><p><text><SENT sid="703" pm="."><plain>Recently, few studies have shown the relationship between CXCR2 gene polymorphisms and human cancer [46,47]. </plain></SENT>
<SENT sid="704" pm="."><plain>The CXCR2 gene polymorphisms were associated with pancreatic cancer but not with prostate and breast cancer [46,47]. </plain></SENT>
<SENT sid="705" pm="."><plain>Kamali-Sarvestini et al. have demonstrated that CXCR2 (+1208) C/T polymorphism is not associated with breast cancer [45]. </plain></SENT>
<SENT sid="706" pm="."><plain>This result is in contrast with our findings. </plain></SENT>
</text></p><p><text><SENT sid="707" pm="."><plain>There is now convincing evidence that these correlations between IL-8 A allele and cancer risk result from an increased level of IL-8 protein, which may have an impact on cancer development and progression via the regulation of immune response and pathways of tumor angiogenesis. </plain></SENT>
</text></p><p><text><SENT sid="708" pm="."><plain>IL-8 is an important chemoattractant that promotes inflammatory processes [9]. </plain></SENT>
<SENT sid="709" pm="."><plain>The IL-8 receptors CXCR1 and CXCR2 have been reported to be present in a variety of cell types including inflammatory cells, endothelial cells, and fibroblasts [46]. </plain></SENT>
<SENT sid="710" pm="."><plain>Consequently, IL-8 is a major contributing factor involved in the initiation and amplification of the inflammatory response via its receptors [48]. </plain></SENT>
<SENT sid="711" pm="."><plain>However, it is known that inflammation profoundly affects the development and progression of tumor and therefore, IL-8 might promote tumor cell proliferation by amplification of inflammation in the tumor microenvironnement via its receptors. </plain></SENT>
</text></p><p><text><SENT sid="712" pm="."><plain>IL-8 proangiogenic effects additionally stem from its ability to inhibit the apoptosis of endothelial cells [49]. </plain></SENT>
<SENT sid="713" pm="."><plain>This inhibition is associated with increased levels of the anti-apoptotic factors Bcl-xl and Bcl-2 as well as with decreased levels of Bax. </plain></SENT>
<SENT sid="714" pm="."><plain>It was further shown that IL-8 stimulates increased endothelial cell mRNA expression of matrix metalloproteinases (MMPs) MMP-2 and -9 as well as increases gelatine activity [49]. </plain></SENT>
<SENT sid="715" pm="."><plain>These MMP activities are required for the proteolytic modifications of basements membranes and extracellular matrices during angiogenesis. </plain></SENT>
</text></p><p><text><SENT sid="716" pm="."><plain>IL-8 was shown to act as an autocrine growth factor and to stimulate invasion and chemotaxis of many tumor cell types. </plain></SENT>
<SENT sid="717" pm="."><plain>The expression of IL-8 and the receptor of ELR+CXC chemokine CXCR2 in cancer have been evaluated in numerous studies. </plain></SENT>
<SENT sid="718" pm="."><plain>Overexpression of IL-8 is associated with increasing tumor stage, disease progression and recurrence in human bladder, prostate, breast, lung, gastric, hepatic cancers, and melanoma [11,14-16,43,50,51]. </plain></SENT>
<SENT sid="719" pm="."><plain>Recently, it has been shown that the ER-negative breast cancer cells overexpressed IL-8. </plain></SENT>
<SENT sid="720" pm="."><plain>Concerning IL-8 receptors, it has been observed that CXCR1 expression was extremely low in breast cancer cells, whereas most of the cells investigated showed a higher expression of CXCR2 [52]. </plain></SENT>
<SENT sid="721" pm="."><plain>The same study also suggested that IL-8 expression is negatively correlated to ER-status and is expressed preferentially in invasive cancer cells [52]. </plain></SENT>
<SENT sid="722" pm="."><plain>Moreover, our data showed that the higher percentage of ER-negative tumors were present in patients carrying the IL-8 (-251) A allele which is associated with a higher IL-8 production. </plain></SENT>
<SENT sid="723" pm="."><plain>Altogether, these results suggested that the genetic variation in the promoter of the IL-8 gene which influences the production of this chemokine could be the genetic basis of the potential tumor progression and invasiveness of breast cancer. </plain></SENT>
</text></p><p><text><SENT sid="724" pm="."><plain>The ability of IL-8 to elicit angiogenic activity depends on the endothelial cell expression of its receptors. </plain></SENT>
<SENT sid="725" pm="."><plain>Recent studies indicated that CXCR1 and CXCR2 are highly expressed on human microvascular endothelial cells (HMEC) [53]. </plain></SENT>
<SENT sid="726" pm="."><plain>Antibodies directed at CXCR1 and CXCR2 are capable of inhibiting IL-8 induced migration of HMEC, which indicates that these two receptors are critical for the IL-8 angiogenic response. </plain></SENT>
<SENT sid="727" pm="."><plain>Since CXCR2 binds to all ELR+CXC chemokines that induce angiogenesis, including IL-8, it may be safe to say that CXCR2 is a mediator of the proangiogenic effects of IL-8. </plain></SENT>
</text></p><p><text><SENT sid="728" pm="."><plain>Several reports have confirmed the importance of CXCR2 in mediating the effects of angiogenesis in human microvascular endothelial cells [18,36,53]. </plain></SENT>
<SENT sid="729" pm="."><plain>Endothelial cells were found to express CXCR2 in vitro and in vivo, but not CXCR1. </plain></SENT>
<SENT sid="730" pm="."><plain>Blocking the function of CXCR2 by either neutralizing antibodies or inhibiting downstream signalling using specific inhibitors of ERK1/2 and PI3 kinase impaired IL-8-induced stress fiber assembly, chemotaxis, and endothelial tube formation in endothelial cells [39,54]. </plain></SENT>
<SENT sid="731" pm="."><plain>Overall, these data strongly support a role for CXCR2 in angiogenesis induced by ELR+CXC chemokines and especially by IL-8. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec><title><text><SENT sid="732" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="733" pm="."><plain>In summary, our data suggests that IL-8 (-251) T/A and CXCR2 (+1208) C/T polymorphisms are likely to play a major role in susceptibility to and prognosis in breast carcinoma. </plain></SENT>
<SENT sid="734" pm="."><plain>Although additional studies on a larger scale will be required to confirm and extend our findings, the present data suggest for the first time that CXCR2 (+1208) C/T polymorphism represents a risk factor for poorer prognosis and susceptibility to breast carcinoma. </plain></SENT>
<SENT sid="735" pm="."><plain>Furthermore, this study provides support for the multigenetic effects of the variant alleles from IL-8, and CXCR2, resulting in a significantly increased risk for breast cancer in the Tunisian population. </plain></SENT>
<SENT sid="736" pm="."><plain>Our findings also reinforce the role attributed to inflammation, angiogenesis, and their mediators as major contributing factors in the process of breast tumor development, progression and aggressiveness. </plain></SENT>
<SENT sid="737" pm="."><plain>Using the IL-8 (-251) T/A and CXCR2 (+1208) C/T polymorphisms alone or in combination with other genetic polymorphisms in angiogenic and inflammatory genes to predict breast carcinoma outcome and prognosis may therefore have an important clinical significance. </plain></SENT>
</text></p></sec></SecTag><SecTag type="COMP_INT"><sec><title><text><SENT sid="738" pm="."><plain>Competing interests </plain></SENT>
</text></title><p><text><SENT sid="739" pm="."><plain>The authors declare that they have no competing interests. </plain></SENT>
</text></p></sec></SecTag><SecTag type="AUTH_CONT"><sec><title><text><SENT sid="740" pm="."><plain>Authors' contributions </plain></SENT>
</text></title><p><text><SENT sid="741" pm="."><plain>SK conceived the manuscript, conducted data analysis, and drafted the manuscript. </plain></SENT>
<SENT sid="742" pm="."><plain>MW contributed to the design and management of data. </plain></SENT>
<SENT sid="743" pm="."><plain>HK, MF and NB provided samples and clinical information. </plain></SENT>
<SENT sid="744" pm="."><plain>LC designed and participated in the data analysis and interpretation of the study. </plain></SENT>
<SENT sid="745" pm="."><plain>AN-H contributed to reviewing the manuscript. </plain></SENT>
<SENT sid="746" pm="."><plain>All authors read and approved the final manuscript. </plain></SENT>
</text></p></sec></SecTag><sec><title><text><SENT sid="747" pm="."><plain>Pre-publication history </plain></SENT>
</text></title><p><text><SENT sid="748" pm="."><plain>The pre-publication history for this paper can be accessed here: </plain></SENT>
</text></p><p><text><SENT sid="749" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/10/283/prepub">http://www.biomedcentral.com/1471-2407/10/283/prepub</ext-link> </plain></SENT>
</text></p></sec></body><back><SecTag type="ACK_FUND"><sec><title>Acknowledgements</title><p><text4fund><text><SENT sid="750" pm="."><plain>This work is supported by le Ministère de l'Enseignement Supérieur et de la recherche scientifique and by le Ministère de la santé Publique de la République Tunisienne. </plain></SENT>
<SENT sid="751" pm="."><plain>We would like to thank Mr Adel Rdissi for English revision. </plain></SENT>
</text></text4fund></p></sec></SecTag><SecTag type="REF"><ref-list><ref id="B1"><text><SENT sid="752" pm="."><plain>American Cancer Society Facts and Figures2005<ext-link ext-link-type="uri" xlink:href="http://www.cancer.org">http://www.cancer.org</ext-link> </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="753" pm="."><plain>World Health Organization Facts and Figures<ext-link ext-link-type="uri" xlink:href="http://www.who.int">http://www.who.int</ext-link> </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="754" pm="."><plain>AntoniouACPharoahPDMcMullanGDayNEPonderBAEastonDEvidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based studyGenet Epidemiol20012111810.1002/gepi.101411443730 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="755" pm="."><plain>LusterADChemokines-chemotactic cytokines that mediate inflammationN Engl J Med199833874364510.1056/NEJM1998021233807069459648 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="756" pm="."><plain>RollinsBJChemokinesBlood199790909289242519 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="757" pm="."><plain>StrieterRMBurdickMDGompertsBNBelperioJAKeaneMPCXC chemokines in angiogenesisCytokine Growth Factor Rev20051659360910.1016/j.cytogfr.2005.04.00716046180 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="758" pm="."><plain>StrieterRMPolveriniPJKunkelSLArenbergDABurdickMDKasperJThe functionnal role of the ELR motif in CXC chemokine-mediated angiogenesisJ Biol Chem1995270273485710.1074/jbc.270.45.273487592998 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="759" pm="."><plain>StrieterRMBelperioJARoderickJPKeaneMPCXC chemokines in angiogenesis of cancerSemin Cancer Biol20041419520010.1016/j.semcancer.2003.10.00615246055 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="760" pm="."><plain>MatsushimaKBaldwinETMukaidaNInterleukin-8 and MCAF: novel leukocyte recruitment and activity cytokinesChem Immunol1992512362651567543 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="761" pm="."><plain>InoueKSlatonJWKimSJPerrottePEveBYBar-EliMRadinskyRDinneyCPIL-8 expression regulates tumorigenecity and metastasis in human bladder cancerCancer Res20006022909910786697 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="762" pm="."><plain>InoueKSlatonJWEveBYKimSJPerrottePBalbayMDYanoSBar-EliMRadinskyRDinneyCPNInterleukin 8 expression regulates tumorigenecity and metastases in androgen-independent prostate cancerClin Cancer Res2000621041910815938 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="763" pm="."><plain>XieKInterleukin-8 and human cancer biologyCytokine Growth Factor Rev200123759110.1016/S1359-6101(01)00016-8 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="764" pm="."><plain>ArakiSOmoriYLynDSinghRKMeinbachDMSandmanYLokeshwarVBLokeshwarBLInterleukin-8 is a molecular determinant of androgen independence and progression in prostate cancerCancer Res2007671468546210.1158/0008-5472.CAN-07-116217638896 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="765" pm="."><plain>AhmedOIAdelAMDiabDRGobranNSPrognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patientsEgypt J Immunol200613261818689272 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="766" pm="."><plain>MillarHJNemethJAMcCabeFLPikounisBWickstromECirculating human interleukin-8 as an indicator of cancer progression in a nude rat orthotopic human non-small cell lung carcinoma modelCancer Epidemiol Biomarkers Prev200817821808710.1158/1055-9965.EPI-07-291518708412 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="767" pm="."><plain>TaguchiAOhmiyaNShiraiKMabuchiNItohAHirookaYNiwaYGotoHInterleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in JapanCancer Epidemiol Biomarkers Prev2005141124879310.1158/1055-9965.EPI-05-032616284368 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="768" pm="."><plain>MurphyPMThe molecular biology of leucocytes chemoattractant receptorsAnnu Rev Immuno19941259363310.1146/annurev.iy.12.040194.003113 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="769" pm="."><plain>AddisonCLDanielTOBurdickMDLiuHEhlertJEXueYYBuechiLWalzARichmondAStrieterRMThe CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activityJ Immunol2000165952697711046061 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="770" pm="."><plain>MurdochCMonkPNFinnAChemokine receptor expression on human endothelial cellsCytokine1999117041210.1006/cyto.1998.046510479407 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="771" pm="."><plain>MillerLJKurtzmanSHWangYAndersonKHLindquistRRKreutzerDLExpression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissueAnticancer Res19981877819568059 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="772" pm="."><plain>BidwellJKeenLGallagherGKimberlyRHuizingaTMcDermottMFCytokine gene polymorphism in human disease: on-line databases, supplement 1Genes Immun20012617010.1038/sj.gene.636373311393658 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="773" pm="."><plain>MukaidaNShirooMMatsushimaKGenomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8J Immunol19891431366712663993 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="774" pm="."><plain>HullJThompsonAKwiatkowskiDAssociation of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK familiesThorax20005510232710.1136/thorax.55.12.102311083887 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="775" pm="."><plain>LurjeGZhangWSchultheisAMYangDGroshenSHendifarAEHusainHGordonMANagashimaFChangHMLenzHJPolymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancerAnn Oncol2008191017344110.1093/annonc/mdn36818550579 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="776" pm="."><plain>OhyauchiMImataniAYonechiMAsanoNMiuraAIijimaKKoikeTSekineHOharaSShimosegawaTThe polymorphism interleukin 8 -251 A/T influences the susceptibility of Helicobacter pylori related gastric diseases in the Japanese populationGut2005543303510.1136/gut.2003.03305015710978 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="777" pm="."><plain>McCarronSLEdwardsSEvansPRGibbsRDearnaleyDPDoweASouthgateCEastonDFEelesRAHowellWMInfluence of cytokine gene polymorphisms on the development of prostate cancerCancer Res2002621233697212067976 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="778" pm="."><plain>Ben NasrHChahedKMestiriSBouaouinaNSnoussiKChouchaneLAssociation of IL-8 (-251) T/A polymorphism with susceptibility to and aggressiveness of nasopharyngeal carcinomaHum Immunol2007687616910.1016/j.humimm.2007.06.00617869651 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="779" pm="."><plain>RenzoniELympanyPSestiniPDistribution of novel polymorphisms of IL-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitisArthritis Rheum20004316334010.1002/1529-0131(200007)43:7&lt;1633::AID-ANR29&gt;3.0.CO;2-910902769 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="780" pm="."><plain>BarnesPJGenetics and pulmonary medicine: 9. </plain></SENT>
<SENT sid="781" pm="."><plain>Molecular genetics of chronic obstructive pulmonary diseaseThorax1999542455210.1136/thx.54.3.24510325902 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="782" pm="."><plain>SnoussiKMahfoudhWBouaouinaNHelalANChouchaneLGenetic variation in IL-8 associated with increased risk and poor prognosis of breast carcinomaHum Immunol200667132110.1016/j.humimm.2006.03.01816698420 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="783" pm="."><plain>Ben AhmedSAloulouSBibiMLandolsiANouiraMBen FatmaLKallelLGharbiOKhairiHKraiemCBreast cancer detection in Tunisian women: an analysis of a hospital trial involving 729 patientsSanté Publique2002142313510.3917/spub.023.0231 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="784" pm="."><plain>OlerupOZetterquiestHHLA-DR typing by PCR amplification with sequence specific primers (PCR-SSP) in two hours: an alternative to serological DR typing in clinical practice including donor recipient matching in cadaveric transplantationTissue Antigens1992392252910.1111/j.1399-0039.1992.tb01940.x1357775 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="785" pm="."><plain>KaplanELMeirPONonparametric estimation from incomplete observationsJ Am Stat Assoc1958534576110.2307/2281868 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="786" pm="."><plain>PetoRPikeMCArmitagePBreslowNECoxDRHowardSVMantelNMcPhersonKPetoJSmithPGDesign and analysis of randomised clinical trials requiring prolonged observation of each patientBr J Cancer19773516831755 </plain></SENT>
</text></ref><ref id="B35"><text><SENT sid="787" pm="."><plain>CoxDRMcCullaghPSome aspects of analysis of covarianceBiometrics1982385416110.2307/25300407171689 </plain></SENT>
</text></ref><ref id="B36"><text><SENT sid="788" pm="."><plain>HeidemannJOgawaHDwinellMBRafieePMaaserCGockelHRAngiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR-2J Biol Chem200327885081510.1074/jbc.M20823120012496258 </plain></SENT>
</text></ref><ref id="B37"><text><SENT sid="789" pm="."><plain>MestasJBurdickMDReckampKPantuckAFiglinRAStreiterRMThe role of CXCR2/CXCR2 ligand biological axis in renal cell carcinomaJ Immunol2005175853515716210641 </plain></SENT>
</text></ref><ref id="B38"><text><SENT sid="790" pm="."><plain>MurphyCMcGurkMPettigrewJSantinelliAMazzucchelliRJohnstonPGMontironiRWaughDJNonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancerClin Cancer Res20051141172710.1158/1078-0432.CCR-04-151815930347 </plain></SENT>
</text></ref><ref id="B39"><text><SENT sid="791" pm="."><plain>WenteMNKeaneMPBurdickMDFriessHBüchlerMWCeyhanGOReberHAStrieterRMHinesOJBlockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesisCancer Lett20062412221710.1016/j.canlet.2005.10.04116458421 </plain></SENT>
</text></ref><ref id="B40"><text><SENT sid="792" pm="."><plain>LiAVarneyMLSinghRKExpression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentialsClin Cancer Res2001710329830411595728 </plain></SENT>
</text></ref><ref id="B41"><text><SENT sid="793" pm="."><plain>HorikawaTKaizakiYKatoHFurukawaMYoshizakiTExpression of interleukin-8 receptor A predicts poor outcome in patients with nasopharyngeal carcinomaLaryngoscope2005115162710.1097/01.mlg.0000150675.37860.f715630368 </plain></SENT>
</text></ref><ref id="B42"><text><SENT sid="794" pm="."><plain>BenoyIHSalgadoRVan DamPGeboersKVan MarckEScharpéSVermeulenPBDirixLYIncreased serum interleukin-8 patients with early and metastatic breast cancer correlates with early dissemination and survivalClin Cancer Res20041071576210.1158/1078-0432.CCR-04-081215534087 </plain></SENT>
</text></ref><ref id="B43"><text><SENT sid="795" pm="."><plain>Ben-BaruchAInflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactionsBreast Cancer Res20035313610.1186/bcr55412559043 </plain></SENT>
</text></ref><ref id="B44"><text><SENT sid="796" pm="."><plain>SavageSAAbnetCCMarkSDQiaoYLDongZWDawseySMTaylorPRChanockSJVariants of the IL8 and IL8RB genes and risk for gastric cardia adenocarcinoma and esophageal squamous cell carcinomaCancer Epidemiol Biomarkers Prev2004131222515715598788 </plain></SENT>
</text></ref><ref id="B45"><text><SENT sid="797" pm="."><plain>Kamali-SarvestaniEAliparastiMRAtefiSAssociation of interleukin-8 (IL-8 or CXCL8) -251T/A and CXCR2 +1208C/T gene polymorphisms with breast cancerNeoplasma2007546484917949231 </plain></SENT>
</text></ref><ref id="B46"><text><SENT sid="798" pm="."><plain>DanahueTRHinesOJCXCR2 and RET single nucleotide polymorphisms in pancreatic cancerWorld J Surg20093347101510.1007/s00268-008-9826-z19057948 </plain></SENT>
</text></ref><ref id="B47"><text><SENT sid="799" pm="."><plain>YangHPWoodsonKTaylorPRPietinenPAlbanesDVirtamoJTangreaJAGenetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer amon Finnish men in a large cancer prevention trialEur J Cancer Prev20061532495310.1097/01.cej.0000199504.07947.e716679868 </plain></SENT>
</text></ref><ref id="B48"><text><SENT sid="800" pm="."><plain>MorohashiHMiyawakiTNomuraHKunoKMurakamiSMatsushimaKMukaidaNExpression of both types of human interleukin-8 receptors on mature neutrophiles, monocytes, and natural killer cellsJ Leukoc Biol199557180877829970 </plain></SENT>
</text></ref><ref id="B49"><text><SENT sid="801" pm="."><plain>LiADubeySVarneyMLDaveBJSinghRKIL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesisJ Immunol200317033697612626597 </plain></SENT>
</text></ref><ref id="B50"><text><SENT sid="802" pm="."><plain>RenYTung-Ping PoonRTsuiHChenWHZhiLiLauCInterleukin-8 Serum Levels in Patients with Hepatocellular Carcinoma: Correlations with Clinicopathological Features and PrognosisClin Cancer Res200395996600114676125 </plain></SENT>
</text></ref><ref id="B51"><text><SENT sid="803" pm="."><plain>FreundAChauveauCBrouilletJPLucasALacroixMLicznarAVignonFLazennecGIL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cellsOncogene20032222566510.1038/sj.onc.120611312527894 </plain></SENT>
</text></ref><ref id="B52"><text><SENT sid="804" pm="."><plain>SinghSVarneyMSinghRKHost CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasisCancer Res2009692411510.1158/0008-5472.CAN-08-337819147552 </plain></SENT>
</text></ref><ref id="B53"><text><SENT sid="805" pm="."><plain>SalcedoRResauJHHalversonDHudsonEADambachMPowellDWassermanKOppenheimJJDifferential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cellsFASEB J2000141320556410.1096/fj.99-0963com11023990 </plain></SENT>
</text></ref><ref id="B54"><text><SENT sid="806" pm="."><plain>KeaneMPBelperioJAXueYYBurdickMDStrieterRMDepletion of CXCR-2 Inhibits Tumor Growth and angiogenesis in a murine model of lung cancerJournal of Immunology200417228532860 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
